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( i ) 
Systemic lupus erythematosus (SLE) is a prototype autoimmune 
disease characterised by the production of autoantibodies, in particular 
antibodies to native double-stranded DNA. These naturally occurring 
ant ibodies are h e t e r o g e n o u s , exhibiting wide ant igen binding 
characteristics that includes a variety of nucleic acids and other 
biomolecules. While much has been learned in recent years of the fine 
specificity and cross reactivity of anti-DNA antibodies in human and 
murine lupus, neither their production and regulation nor the molecular 
genetics of their formation is known. Autoimmune phenomena manifested 
as antibodies to cellular components have also been described in cancer 
patients. These include anti-nuclear antibodies and antibodies to 
cytoplasmic antigens. Autoantibodies have been detected in patients with 
leukemias, malignant melanomas, lung, breast and hepatocellular 
carcinoma. 
Reactive oxygen species are formed constantly in living organisms, as 
products of the normal metaboHsm, or as a result of different 
environmental influences. ROS have been implicated in a number of 
human degenerative diseases including SLE and cancer. Among the ROS. 
the *OH is the most potent and can react with DNA, lipids and proteins. 
Of the five major DNA components, thymine and cytosine are most 
susceptible to 'OH damage, followed by adenine, guanine and deoxyribose 
moiety. 
In the present thesis, thymidine monophosphate (TMP) was modified 
with hydroxyl radical, generated bv, H^O^ and UV hght. UV absorption and 
difference spectra showed the characteristic loss in absorption pattern as 
a resuh of the damage caused by hydroxyl radical. Antibodies agianst TMP 
and ROS-TMP were induced in rabbits. Both the antigens were found to 
be non-immunogenic. TMP was conjugated to BSA as a carrier protein by 
(ii) 
carbodiimide method to enhance its immunogenicity. TMP-BSA conjugate 
was characterized by UV spectra and PAGE. The results of PAGE reiterate 
the formation of conjugate. TMP-BSA conjugate was modified with 
hydroxyl radical. UV absorption and difference spectra showed 
hypochromicity in the modified conjugate. The formation of ROS-modified 
conjugate was analyzed by Sephadex G-lOO column chromatography, 
densitometric scanning and agarose gel eletrophoresis. The data 
conclusively demonstrates structural perturbations and formation of low 
molecular weight species. 
Induced antibodies against TMP-BSA and ROS-TMP-BSA conjugates 
revealed their high immunogenicity. Antibodies thus formed were purified 
on Sepharose 4B column. Purified anti-TMP-BSA conjugate IgG showed 
95% inhibition (at 10 pg/ml) with TMP-BSA conjugate. Almost similiar 
inhibition of anti-ROS-TMP-BSA conjugate IgG was observed with ROS-
TMP-BSA conjugate. The antigen binding characteristics of purified TMP-
BSA conjugate IgG was investigated with various nucleic acid conformers. 
ROS-TMP-BSA conjugate showed a maximum inhibition of 42%. ROS-
modified TMP, thymidine and thymine showed higher inhibitions of 69%, 
56% and 82% as compared to their native forms. Similiarly, ROS-adenine 
and ROS-guanine show higher inhibition of 57% and 6 1 % than their 
native counterparts. Poly(dA-dT).poly(dA-dT) showed moderate inhibition 
while poly(I), ROS-poly(I) and ROS-poly(G) showed insignificant inhibition. 
Inhibition data showed crossreactivity of anti-ROS-TMP-BSA conjugate 
IgG with various conformers. The TMP-BSA conjugate gave a maximum 
inhibition of 89%. ROS-modified TMP, thymidine and thymine showed 
higher inhibitions (86%, 56% and 81%) than their unmodified 
counterparts (39%, 23% and 16%). PoIy(dA-dU).poly(dA-dU) and poly(dl-
dC).poly(dl-dC) showed inhibition of 35% each. ROS-guanine showed a 
(iii) 
high inhibitory potential of 78% than native guanine (55%). The broad 
antigen binding characteristics of induced antibodies with a variety of 
polynucleotides might be due to recognition of the phosphodiester-
backbone. 
In the present study, anti-double stranded DNA autoantibodies from 
SLE patients were investigated for binding to native and modified 
conjugates. Results with purified SLE IgG showed appreciable binding with 
native DNA (inhibition varies from 32% to 55%). Results of direct binding 
ELISA show preferential binding of TMP-BSA conjugate as compared to 
ROS-modified conjugate. Competition ELISA of purified SLE IgG with 
TMP-BSA conjugate showed maximum inhibition ranging from 32% to 
85% while ROS-modified form show inhibition from 10% to 52%. The 
data substantiated the results of direct binding ELISA. 
The presence of autoantibodies in the sera of cancer patients were 
also studied. Direct binding ELISA of the serum samples from patients 
with breast, lung, Uver and gall bladder cancer showed higher recognition 
of ROS-TMP-BSA conjugate as compared to its native form. Tonsil and 
oral cancer sera recognizes both native and ROS-modified conjugates. Out 
of the six breast cancer sera tested, two showed moderate inhibition with 
TMP-BSA conjugate while two gave similiar binding with native and ROS-
modified conjugates. Among seven serum samples from oral cancer three 
showed higher inhibition with TMP-BSA conjugate as compared to ROS-
modified form. All three liver cances sera had antibodies with a higher 
recognition to ROS-TMP-BSA conjugate as compared to its native form. 
Sera from lung and gall bladder cancer showed preferential recognition 
with ROS-TMP-BSA conjugate. Out of two sera from larynx one showed 
higher inhibition with TMP-BSA conjugate and the other with ROS-TMP-
BSA conjugate. Purified cancer IgG was investigated for antibodies against 
( i v ) 
TMP-BSA and ROS-TMP-BSA conjugates. IgG isolated from breast cancer 
sera showed higher recognition of ROS-modified conjugate over that of 
native conjugate. One of them showed a maximum inhibition of 62% with 
ROS-TMP-BSA conjugate. Two IgG isolated each from liver and gall 
bladder cancer sera showed higher recognition with ROS-TMP-BSA 
conjugate. Out of the five IgGs isolated from oral cancer sera, four 
showed higher binding with TMP-BSA conjugate than towards ROS-
modified conjugate. 
In conclusion, the conjugation of TMP with BSA renders it 
immunogenic. The antibodies raised against TMP-BSA and ROS-TMP-BSA 
conjugates were found to be highly immunogenic and are precipitating in 
nature. The induced antibodies though highly specific for the immunogen. 
exhibited cross reactivity with various nucleic acid polymers, resembling 
the binding chacteristics of SLE anti-DNA antibodies. TMP-BSA conjugate 
provides higher inhibitory potential to SLE anti-DNA autoantibodies which 
might serve as a diagnostic marker for SLE. IgG isolated from sera of 
breast, liver and gall bladder cancer recognize and bind to ROS-modified 
TMP-BSA conjugate. 
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ABSTEACT 
( i ) 
Systemic lupus erythematosus (SLE) is a prototype autoimmune 
disease characterised by the production of autoantibodies, in particular 
antibodies to native double-stranded DNA. These naturally occurring 
an t ibodies are h e t e r o g e n o u s , exhibiting wide ant igen binding 
characteristics that includes a variety of nucleic acids and other 
biomolecules. While much has been learned in recent years of the fine 
specificity and cross reactivity of anti-DNA antibodies in human and 
murine lupus, neither their production and regulation nor the molecular 
genetics of their formation is known. Autoimmune phenomena manifested 
as antibodies to cellular components have also been described in cancer 
patients. These include anti-nuclear antibodies and antibodies to 
cytoplasmic antigens. Autoantibodies have been detected in patients with 
leukemias, malignant melanomas, lung, breast and hepatocellular 
carcinoma. 
Reactive oxygen species are formed constantly in living organisms, as 
products of the normal metabolism, or as a result of different 
environmental influences. ROS have been imphcated in a number of 
human degenerative diseases including SLE and cancer. Among the ROS. 
the *OH is the most potent and can react with DNA, lipids and proteins. 
Of the five major DNA components, thymine and cytosine are most 
susceptible to 'OH damage, followed by adenine, guanine and deoxyribose 
moiety. 
In the present thesis, thymidine monophosphate (TMP) was modified 
with hydroxyl radical, generated by HgO^ and UV hght. UV absorption and 
difference spectra showed the characteristic loss in absorption pattern as 
a result of the damage caused by hydroxyl radical. Antibodies agianst TMP 
and ROS-TMP were induced in rabbits. Both the antigens were found to 
be non-immunogenic. TMP was conjugated to BSA as a carrier protein by 
(ii) 
carbodiimide method to enhance its immunogenicity. TMP-BSA conjugate 
was characterized by UV spectra and PAGE. The results of PAGE reiterate 
the formation of conjugate. TMP-BSA conjugate was modified with 
hydroxy! radical. UV absorption and difference spectra showed 
hypochromicity in the modified conjugate. The formation of ROS-modified 
conjugate was analyzed by Sephadex G-lOO column chromatography, 
densitometric scanning and agarose gel eletrophoresis. The data 
conclusively demonstrates structural perturbations and formation of low 
molecular weight species. 
Induced antibodies against TMP-BSA and ROS-TMP-BSA conjugates 
revealed their high immunogenicity. Antibodies thus formed were purified 
on Sepharose 4B column. Purified anti-TMP-BSA conjugate IgG showed 
95% inhibition (at 10 pg/ml) with TMP-BSA conjugate. Almost similiav 
inhibition of anti-ROS-TMP-BSA conjugate IgG was observed with ROS-
TMP-BSA conjugate. The antigen binding characteristics of purified TMP-
BSA conjugate IgG was investigated with various nucleic acid conformers. 
ROS-TMP-BSA conjugate showed a maximum inhibition of 42%. ROS-
modified TMP, thymidine and thymine showed higher inhibitions of 69%. 
56% and 82% as compared to their native forms. Simiharly, ROS-adenine 
and ROS-guanine show higher inhibition of 57% and 6 1 % than their 
native counterparts. Poly(dA-dT).poly(dA-dT) showed moderate inhibition 
while poly (I), ROS-poly{I) and ROS-poly(G) showed insignificant inhibition. 
Inhibition data showed crossreactivity of anti-ROS-TMP-BSA conjugate 
IgG with various conformers. The TMP-BSA conjugate gave a maximum 
inhibition of 89%. ROS-modified TMP, thymidine and thymine showed 
higher inhibitions (86%, 56% and 81%) than their unmodified 
counterparts (39%, 2 3 % and 16%). PoIy(dA-dU).poly(dA-dU) and poly(dI-
dC).poly(dl-dC) showed inhibition of 35% each. ROS-guanine showed a 
(iii) 
high inhibitory potential of 78% than native guanine (55%). The broad 
antigen binding characteristics of induced antibodies with a variety of 
polynucleotides might be due to recognition of the phosphodiester-
backbone. 
In the present study, anti-double stranded DNA autoantibodies from 
SLE patients were investigated for binding to native and modified 
conjugates. Results with purified SLE IgG showed appreciable binding with 
native DNA (inhibition varies from 32% to 55%). Results of direct binding 
ELISA show preferential binding of TMP-BSA conjugate as compared to 
ROS-modified conjugate. Competition ELISA of purified SLE IgG with 
TMP-BSA conjugate showed maximum inhibition ranging from 32% to 
85% while ROS-modified form show inhibition from 10% to 52%. The 
data substantiated the results of direct binding ELISA. 
The presence of autoantibodies in the sera of cancer patients were 
also studied. Direct binding ELISA of the serum samples from patients 
with breast, lung, liver and gall bladder cancer showed higher recognition 
of ROS-TMP-BSA conjugate as compared to its native form. Tonsil and 
oral cancer sera recognizes both native and ROS-modified conjugates. Out 
of the six breast cancer sera tested, two showed moderate inhibition with 
TMP-BSA conjugate while two gave simiHar binding with native and ROS-
modified conjugates. Among seven serum samples from oral cancer three 
showed higher inhibition with TMP-BSA conjugate as comparec' to ROS-
modified form. All three liver cancer sera had antibodies with a higher 
recognition to ROS-TMP-BSA conjugate as compared to its native form. 
Sera from lung and gall bladder cancer showed preferential recognition 
with ROS-TMP-BSA conjugate. Out of two sera from larynx one showed 
higher inhibition with TMP-BSA conjugate and the other with ROS-TMP-
BSA conjugate. Purified cancer IgG was investigated for antibodies against 
(iv) 
TMP-BSA and ROS-TMP-BSA conjugates. IgG isolated from breast cancer 
sera showed higher recognition of ROS-modified conjugate over that of 
native conjugate. One of them showed a maximum inhibition of 62% with 
ROS-TMP-BSA conjugate. Two IgG isolated each from liver and gall 
bladder cancer sera showed higher recognition with ROS-TMP-BSA 
conjugate. Out of the five IgGs isolated from oral cancer sera, four 
showed higher binding with TMP-BSA conjugate than towards ROS-
modified conjugate. 
In conclusion, the conjugation of TMP with BSA renders it 
immunogenic. The antibodies raised against TMP-BSA and ROS-TMP-BSA 
conjugates were found to be highly immunogenic and are precipitating in 
nature. The induced antibodies though highly specific for the immunogen. 
exhibited cross reactivity with various nucleic acid polymers, resembling 
the binding chacteristics of SLE anti-DNA antibodies. TMP-BSA conjugate 
provides higher inhibitory potential to SLE anti-DNA autoantibodies which 
might serve as a diagnostic marker for SLE. IgG isolated from sera of 
breast, liver and gall bladder cancer recognize and bind to ROS-modified 
TMP-BSA conjugate. 
(v) 
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IKTEODUCTION 
The mammalian immune system functions through complex 
interactions between various cells and their products. Antigen specific 
responses by the immune system are effected by B and T lymphocytes; T 
cells mediate cellular immunity (for example, graft rejection) and B cells 
mediate humoral immunity (antibody production). Other cell types such as 
macrophages and natural killer cells act non-specifically to eliminate 
foreign elements. Discrimination between self and non-self is an important 
feature of the immune system. Normally, immunologic attack is directed 
against agents which are foreign such as bacteria, virusus, parasites and 
some internal changes, while it does not respond to self antigens. Since 
the early studies of Ehrlich, immunologists have demonstrated the 
presence of autoantibodies in the sera of patients with various diseases. A 
hallmark of most autoimmune diseases is the presence of autoantibodies 
against self antigens. 
Autoimmunity and Autoimmune Disorders 
Grabar (1975) considered autoimmunity as a normal physiological 
phenomenon, in which the immunological mechanisms are not necessarily 
'a defense' but a physiological system of transport of metabolic and 
catabolic substances, i.e., a 'cleaning up ' of the organism of residual 
products and it is the application and extension of this mechanism which 
may act as a defense against foreign substances. Autoimmune diseases are 
those which result from immunologic reactions, humoral and cellular, 
directed against the individual's own tissue components (Deodhar, 1992). 
An autoimmune disease may be organ/tissue specific, e.g., Hashimoto's 
syndrome, thyrotoxicosis, pernicious anemia or non-organ/tissue specific 
(systemic) such as systemic lupus erythematosus (SLE) and progressive 
systemic sclerosis (PSS). These may destroy, mimic or enhance the target 
and can range in severity from being mild to fatal (Minard, 1989). There 
is no single theory that can explain all the features of autoimmune 
diseases. Shoenfeld and Isenberg (1989) suggested that the wide spectrum 
of autoimmune diseases as the 'mosaic' of autoimmunity with its many 
factors, like genetic, hormonal, immunological and environmental leading 
to diverse diseases. 
Autoimmune diseases show a highly significant familial predisposition 
(Arnett, 1992; Hochberg, 1987). Relatives of a patient with a given 
autoimmune disease are known to be at a high risk for developing the 
same disease. Also, multiple autoimmune diseases are known to occur in 
the same patient. These findings suggest involvement of genetic factors 
which has been linked to the human leucocyte antigen (HLA) system, 
particularly the HLA-DR sublocus. The HLA genes function as secondary 
genes to allow expression of specific autoantibody (Bias et al., 1986). 
Polyclonal B cell activation has been proposed as a possible mechanism 
that may be responsible for the over activation of B cells and production 
of autoantibodies in certain autoimmune diseases, particularly SLE 
(Klinman et al., 1990; Dziarski, 1988). In autoimmune prone individuals, 
B cells are hyper-responsive to polyclonal activators and undergo initial 
activation including expression of autoreactive clones, under the influence 
of exogenous or endogenous polyclonal activators. Various polyclonal B 
cell activators such as Epstein Barr virus (EBV) and its components, 
endotoxin or lipopolysaccharide (LPS), certain bacterial agents and drugs 
may function by bypassing T cell regulatory mechanisms and activating B 
cells directly. The best example of human autoimmune disease in which 
such direct polyclonal activation may play a role is autoimmune thyroiditis 
(Goodman and Weigle, 1981). 
TABLE I 
Autoimmune Diseases and Their Respective Autoantibodies 
Diseases Autoantibodies directed against 
SLE and related diseases 
Systemic lupus 
erythematosus 
Scleroderma (PSS) 
Sjogren's syndrome 
Mixed connective 
tissue disease 
Rheumatoid arthritis 
Other autoimmune diseases 
Autoimmune thyroid 
diseases 
Addison's disease 
Pernicious anemia 
Inflammatory bowel 
disease 
Chronic active hepatitis 
Primary biliary cirrhosis 
Mysthenia gravis 
Pemphigus vulgaris 
substance 
Bullous pemphigoid 
Autoimmune hemolytic 
anemia 
Multiple sclerosis and 
relating de-myelinating 
diseases 
nuclear antigens (DNA, Sm, cardiolipin) 
nuclear antigens (Scl-1, Scl-70) 
nuclear antigens (SS-A, SS-B) 
extractable nuclear antigen (RNP) 
Fc portion of IgG (rheumatoid factor), 
nuclear antigens 
thyroglobulin, microsomal antigen, TSl 
adrenal cortical cell antigen 
intrinsic factor, parietal cell antigen 
colonic mucosal antigen 
smooth muscle antigen 
mitochondrial antigen 
acetylcholine receptor 
epidermal intercellular 
skin basement membrane 
red cell membrane antigen 
myelin basic protein antigen 
(adapted from Deodhar, 1992) 
The immune response is controlled mainly by the regulatory influence 
of T-lymphocyte subsets, T-helper and T-suppressor cells. In most 
autoimmune diseases, there is a significant decrease in T-suppressor cell 
numbers and activity, which accounts for the increased T-helper/T-
suppressor cell ratio. For example, in SLE the prototype of autoimmune 
diseases, there is a significant decrease in T-suppressor cells during active 
phases of the disease (Deodhar, 1992). The increased T-helper/T-
suppressor cell ratio has been noted in a wide variety of autoimmune 
diseases, such as SLE, Sjogren's syndrome, progressive systemic sclerosis, 
rheumatoid arthritis, pernicious anemia, multiple sclerosis, immune 
complex mediated renal diseases and many others. 
In acquired immune deficiency syndrome (AIDS), the presence of 
autoantibodies in respective autoimmune diseases have been demonstrated 
in recent years (Calabrese, 1988). The autoantibodies associated with HIV 
infection have included anti-nuclear, rheumatoid factor, anti-cardiolipin, 
anti-platelet, anti-red blood cell and anti-lymphocyte antibodies. The 
mechanisms by which viruses and other infectious agents initiate 
autoimmune phenomena are probably complex and it may include 
structural similarity, increased HLA expression, polyclonal B cell 
activation and alteration of the antigen (Shoenfeld and Isenberg. 1989). 
Hormonal factors such as sex hormones , thymic hormones and 
corticosteroids play a significant role. It has been reported that 
testosterone and thymic hormones enhance CD8^ T cell receptor function 
(Lahita and Kunkel, 1984), whereas estrogen may suppress this function 
(Talal and Ahmad, 1987). The female relatives of patients with certain 
autoimmune diseases have been reported to demonstrate a significant 
prevalence of autoantibodies and suppressor T cell defects (Miller and 
Schwartz, 1982). 
Tolerance is a state of immunologic non-responsiveness to a 
substance that would be expected to evoke an immune response. 
Tolerance provides an essential mechanism for the prevention of 
selfinjury. Tolerance is accompHshed through three mechanisms: thymic 
education, thymic deletion and peripheral tolerance. Thymus is the major 
site for 'self-nonself discrimination. It is here that the T cell repertoire is 
determined. Some cells are programmed to die (negative selection) while 
others are not (positive selection) (Adorini, 1993). Errors in central or 
peripheral tolerance at the T or B cell level have also been suggested as 
probable causes for autoimmunity. It has also been suggested that thymus 
is the critical time keeper with aging process with respect to immune 
responses (Rose, 1994). As the thymic cortex atrophies, the response to 
self antigen rises, generating the aging paradox. 
Antigenicity of DNA 
Native DNA has not been found an effective immunogen in normal 
experimental animals but antibodies that react with B-conformation 
(native DNA) are found in individuals with autoimmune diseases, most 
commonly in systemic lupus erythematosus (SLE) (Stollar, 1989 ; Karounos 
et a/., 1988; Tan, 1982). Haskowa et al. (1959) immunized rabbits with 
DNA of thymus or Ehrlich ascites tumor cells, no antibodies were 
de tec ted by complemen t f ixation, gel diffusion or passive 
hemagglutination. Wilson et al. (1965) found that 36 rabbits failed to 
respond to calf thymus DNA. Negative results were also obtained on the 
injection of purified native or denatured salmon, calf thymus, phage T4 or 
£. coli DNA (Levine and Stollar, 1968; Barnett and Vaughan, 1966; 
Plescia et al., 1964; Pasternak et a/., 1960). 
The specificity of anti-DNA antibodies has been analysed in order to 
understand the nature of epitope responsible for their production (Stollar, 
1986). Anti-DNA antibodies react to a variety of determinants on both 
single stranded (ss) and double stranded (ds) DNA (Diamond et a/., 1992; 
Tillman, 1992; Shlomchik et a/., 1990; Marion et al., 1989). Although, 
the precise mechanism of anti-dsDNA antibody production remains 
unknown, studies point to a role of DNA antigen drive (Radic et al.. 
1989). Anti-dsDNA antibodies display pattern of variable (V) region gene 
utilization that resemble conventional responses in the content of somatic 
mutations (Hirose et a/., 1993; O'Keefe et al., 1992; Shlomchik et a/., 
1987). Since these mutations are associated with enhanced binding, to 
DNA, it is likely that DNA is the selecting antigen in viuo. Among 
structural features associated with dsDNA binding, a high content of 
arginine residues in the third complementary determining region (CDR3) 
of the heavy chain appears important (Shlomchik et al., 1990 &1987). 
Recent studies have, however, shown that DNA complexes with a 
synthetic peptide, Fus-1 can induce an anti-dsDNA response in mice 
(Desai et al., 1993) . Anti-DNA antibodies may also result by 
autoimmunizat ion with chromatin, ra ther t h a n native DNA 
(Theofilopoulos, 1995). Immunization of experimental animals with 
denatured DNA , synthetic polynucleotides Uke poly(dT), poly(dC), poly (A), 
poly(I), poly(G), double stranded RNA, left handed Z-DNA and chemically 
modified DNA can induced immune responses (Anderson et al., 1988; 
Stollar, 1986). The immunogenicity of certain dsDNA stuctures has been 
well documented in animal models. Z-DNA, a left handed helix, induces a 
significant antibody response in experimental animals (Madaio et al.. 
1984). The induced antibodies are highly specific for Z-DNA and do not 
bind to right handed B-DNA (Bunyard and Pisetsky, 1994). Antibodies 
reactive with left handed Z-DNA arise spontaneously in the sera of 
patients with SLE and rheumatoid arthritis and in auto-immune MRL/lpr 
mice (Pisetsky et al., 1990). 
DNA from various bacterial species elicit high titer responses in 
normal mic.e when immunized as complexes with methylated bovine serum 
albumin (MBSA) (Gilkeson et a/., 1989a & b). Studies have shown that 
bacterial DNA differs from mammaUan DNA in its content of pyrimidine 
clusters, patterns of base methylation and in many of its coding sequences 
(Wells, 1988; Cheng et al., 1985 ; Szybalski et al., 1966). Together 
these features could create local regions in bacterial DNA that are 
structurally distinct and rarely present in mammalian DNA. The DNA from 
two bacterial species, Micrococcus lifsodeiktus and Staphi)lococcus 
epidermldis, was recognised by normal human sera. This finding was in 
contrast to normal dogma that anti-DNA antibodies are prevalant in SLE 
alone (Fredriksen, 1991). The immune response to foreign DNA is 
analogous to that of foreign proteins in that, it does not require T cell 
recognition. The antibodies are of IgG2 isotype, where as lupus anti-DNA 
are predominantly IgGl and lgG3 (Pisetsky, 1997; Pisetsky and Drayton, 
1997; Tsujimura et al., 1997; Kay et al., 1988). This pattern of isotype 
expression suggests that the responses to foreign DNA are distinct from 
the lupus anti-DNA response, which appears to be Tcell dependent 
(Robertson et al., 1992). 
Free Radical Biochemistry 
A free radical is any species capable of independent existence that 
contains one or more unpaired electrons. It is now established that free 
radicals and other reactive oxygen species are continuously produced in 
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vivo (Halliwell, 1993). In consequence, organisms have evolved not only 
antioxidant defense systems to protect against them, but also repair 
systems that prevent the accumulation of oxidatively-damaged molecules 
(Sies, 1991 & 1985; Fridovich, 1989; Halliwell and Gutteridge, 1989). 
The term 'reactive oxygen species' (ROS) is a collective one that 
includes not only oxygen-centered radicals such as superoxide (O^') and 
hydroxyl (*0H ), but also some non-radical derivatives of oxygen (O^), such 
as hydrogen peroxide (H2O2), singlet oxygen (^Oj,), hypochlorous acid 
(HOCl) and ozone (O^) (Halliwell, 1993). Most molecules are non-radicals. 
When radicals react with non-radicals, new radicals are generated. Only 
when two radicals meet and join their unpaired electrons, are the radicals 
lost. The usual major route for metabolism of molecular oxygen involves 
its complete reduction to HgO by accepting four electrons (Thornalley and 
Bannister, 1985; Fridovich, 1978; Freiden and Osaki, 1970). However, 
with one electron reduction, several free radicals and H-fi^ ^^" ^® formed 
(Byung, 1994). 
O2 + e- — > 0„ superoxide radical 
O3 + H3O —> HO, + OH hydroperoxyl radical 
HO2 + e- + H •> H,03 hydrogen peroxide 
H , 0 , -h e —> OH + OH' hydroxyl radical 
Superoxide Radical 
The free radical, superoxide anion {O./') is formed by the addition of 
one electron to ground state dioxygen. It is unstable in aqueous solutions, 
due to its spontaneous reactivity with itself producing hydrogen peroxide 
(H^O )^ and molecular oxygen (O^) (dismutation reaction) (Cadenas, 1989; 
Halliwell and Gutteridge, 1984; Fridovich, 1983). The superoxide radical 
in its protonated form is known as perhydroxyl radical (HO^), which 
exhibits even higher reactivity. 
O 2 " + O ^ " + 2H* —> H2O2 + O2 
Hydrogen Peroxide 
Hydrogen peroxide is the protonated form of peroxide ion {O.^^"), formed 
by the reduction of two electrons of molecular oxygen. Although, H^O.^ by 
definition is not considered an oxygen free radical, it nevertheless remains 
the most extensively studied oxygen metabolite (Harris, 1992). The 
dismutation of O^' by superoxide dismutase is a major source of HgO^. 
SOD 
^2" + O 2 " + 2H* > H2O2 + O2 
HgOg is very harmful to cells because it may cross biological 
membranes and can also lead to the formation of highly reactive hydroxyl 
radical (OH) (Aruoma et aJ., 1 9 9 1 ; Pryor and Church. 1991 ; Pryor. 
1986; Mello-Filho et a/., 1984; Jones et al., 1981). 
Hvdroxvl Radical 
Hydroxyl radical is an extremely reactive chemical species which can 
react with any biological molecule. Both, its half life (fraction of 
microseconds) and radius of action (30°A) are very small. The 0^'~ and H^O^ 
are less reactive oxidants than "OH but they have a longer Hfe time which 
allows them to react with molecules in locations far from the site of their 
production (Pryor, 1986; Halliwell and Gutteridge, 1984). The hydroxyl 
radical is produced in Hving systems by at least two mechanisms: reaction 
of transition metal ions with HgO^ and homolytic fission of water due to 
its background exposure to ionizing radiation (von Sonntag. 1987). First. 
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hydroxyl radicals are derived from the decomposition of hydrogen 
peroxide via the Fenton reaction (Fenton, 1894) 
Fe2* + H2O2 —> Fe^* + 'OH + O H ' 
and second, by the interaction of superoxide with hydrogen peroxide 
through the Habcr-Weiss reaction (Haber and Weiss, 1934). 
0 - - + H^O, —> O., + H^O + OH 
Free Radical Product ion in Biological Sys tems 
Oxygen free radicals are being continuously produced in organisms 
and many of them are necessary to carry out certain biological reactions 
(Martinez-Cayuela, 1995). In addition to exogenous sources of free 
radicals such as ionizing radiation, tobacco smoke, pesticides and 
pollutants, oxygen free radicals are also produced by intracellular systems. 
The autoxidation of small soluble molecules in the cellular cytoplasm 
may lead to the production of oxygen free radicals by concomitant O^ 
reduction. Examples include catecholamines, flavins, tetrahydroproteins. 
quinones and thiols (Proctor and Reynolds, 1984; Fridovich, 1978). Some 
cytoplasmic enzymes generate oxygen free radicals as products of their 
catalytic cycles e.g., xanthine oxidase and aldehyde dehydrogenase 
(Southern and Powis, 1988; Freeman and Grapo, 1982; Rajagopalan. 
1980). Hemoglobin may be oxidized producing oxygen free radicals. 
However, a small quantity of oxyhemoglobin is only transformed into 
methemogiobin due to the action of methemoglobin reductases (Valenzuela 
and Videla, 1989; Clark and Cowden, 1985; Halliwell and Gutteridge. 
1984; Proctor and Reynolds, 1984). Reactions catalysed by lipoxygenase 
and cyclooxygenase in the synthetic pathway of leukotrienes. 
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thromboxanes and prostaglandins involve oxygen free radical production 
(Blake et al., 1987; Mottley et al., 1982; Mason et ai, 1980). These 
radicals, which deactivate the cyclooxygenase enzyme, can be an 
important feed back control of prostaglandin synthesis. A main source of 
Og is the respiratory burst of phagocytic cells when they are activated. 
This process is due to an enzyme, reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase, located on the external surface 
of the plasmic membrane. 
Cytochrome c oxidase from the mitochondrial electron transport 
system catalyzes molecular oxygen reduction to HgO by acquiring four 
electrons and four protons. Autoxidation of ubiquinone and NADH 
dehydrogenase produces superoxide radicals (Beyer, 1990; Freeman and 
Grapo, 1982; Turrens and Boveris, 1980). Cytochromes P450 and b5 of 
the microsomic electron transport systems generate oxygen free radicals. 
During the catalytic cycle of these cytochromes, superoxide radicals may 
be formed (Sevanian et al., 1990; Valenzuela and Videla, 1989; Rush and 
Bielski, 1985). Cytochrome reductases involved in redox reactions of 
cytochromes P450 and b5 can also produce superoxide radicals and H^O^. 
when they undergo autoxidation (Sevanian et al., 1990; Freeman and 
Grapo, 1982). 
DNA Damage and its Repair 
The air we breathe is a double edged sword. It is of course, 
fundamental for life; yet, many intracellular reactions in which it 
participates results in the formation of oxygen-derived free radicals. These 
highly reactive electrophilic chemical species can not only permanently 
damage cells by reacting with nucleic acids, proteins and polyunsaturated 
lipids (Hpid peroxidation) but may also lead to cell death (Knight. 1995). 
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The endogenous reactions that are likely to contribute to DNA 
damage are oxidation, methylation, depurination and deamination (Ames. 
1989). The chemistry of DNA damage by several ROS has been well 
characterized in vitro (Box et al., 1995; Epe, 1993; Steeken, 1989; von 
Sonntag, 1987). Different ROS affect DNA in different ways e.g. O^ and 
H2O2 do not react with DNA bases at all (Halliwell and Aruoma, 1991). 
while OH generates a multiplicity of products from all four DNA bases 
(Halliwell and Aruoma, 1991). Of the five major DNA components, 
thymine and cytosine are most susceptible to OH damage, followed by 
adenine, guanine and deoxyribose moiety (Saul et al., 1987). 8-
hydroxyguanine (8-OH-G), is considered to be an excellant marker of 
oxidative DNA damage (Tritscher et aL, 1996; Lunec et al., 1994; 
Shibutani et al., 1991), due to its high mutagenic potential (Musarrat and 
Wani, 1994; Guyton and Kensler, 1993; Kasai and Nishimura. 1991: 
Ames and Gold, 1991). It has been shown that 8-hydroxydeoxyguanine 
causes GC—>AT base pair substitutions (Kuchino et al., 1987), which can 
result in the activation of human C-Ha-ras-1 oncogene (Kamiya et al.. 
1992). 
There is evidence to implicate oxygen free radical damage in the 
etiology of many chronic health problems such as emphysema, 
cardiovascular and inflammatory diseases, cataracts and cancer (Machlin 
and Bendich, 1987). TableII presents a Hst of diseases that involve radical 
reactions in mammalian systems (Knight, 1995). The data from studies on 
humans indicate that the important determinants of oxidative damage rate 
includes tobacco smoking, oxygen consumption and some inflammatory 
diseases, whereas diet composition, energy restriction and antioxidant 
supplements have a minimal influence (Brown et al., 1995; Lunec et al., 
1994; Bashir et al., 1993; Tagesson, 1992). 
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TABLE II 
Diseases / Disorders Linked to Oxygen Free Radicals 
Y. Ageing 
2. Atherosclerosis 
a) heart disease 
b) stroke 
3. Brain disorders 
a) hyperbasic oxygen 
b) aluminium toxicity 
c) neuronal lipofuscinoses 
d) neurotoxins 
4. Cancer 
5. Cardiac myopathy 
a) Keshan disease 
6. Chronic granulomatosus disease 
7. Diabetes mellitus 
8. Eye disorder 
a) macular degeneration 
b) cataract ogenesis 
9. Inflammatory disorders 
10. Lung disorders 
a) asbestosis 
b) oxygen toxicity 
c) emphysema 
11. Nutritional deficiencies 
12. Radiation injury 
13. Repurfusion injury 
14. Rheumatoid arthritis 
15. Skin disorders 
a) solar radiation 
b) burns 
c) contact dermatitis 
d) Bloom syndrome 
16. Toxic states 
a) xenobiotics 
b) metal ions 
(adapted from Knight, 1995) 
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Oxidative damage to DNA has been proposed to be an important 
factor in carcinogenesis, a suggestion supported by experimental studies 
on animals and in uitro (Loft and Poulsen. 1996; Ames et al., 1995; 
Fraga et al., 1990; Lunec, 1990; Ames, 1989). The products of repair of 
these lesions are excreted in the urine and the rate of excretion of repair 
products in terms of oxidized bases reflect the average rate of oxidative 
DNA damage in the body (Loft and Poulsen, 1998). Among the possible 
repair products from oxidat ive DNA modif icat ion, 8-oxo-2 ' -
deoxyguanosine (8-oxodG), 8-oxoguanine (8-oxoGua), thymine glycol (Tg). 
thymidine glycol (dTg) and 5-hydroxymethyl uracil (5-OHmU) have so far 
been identified in urine (Fig. 1) (Loft and Poulsen, 1996; Suzuki et al.. 
1995; Faure et al., 1993; Shigenaga et al., 1989; Cathcart et a!.. 
1984). The levels of oxidized bases in lymphocyte DNA or other 
accessible cells will reflect the steady state levels i.e., the balance between 
damage and repair (Loft and Poulsen, 1998). 
Oxidative DNA damage is repaired in viuo by a variety of enzymes. 
Strand breaks are annealed and modified bases are excised as such or as 
nucleotides (Demple and Harrison, 1994; Ramoter and Demple, 1993). 
DNA glycosylases excise bases and subsequently phosphodiester bonds on 
each side of the abasic site are incised by end ©nucleases, allowing 
insertion of an intact nucleotide (Loft and Poulsen, 1996). Some enzymes 
such as endonuclease III possess both glycosylase and endonuclease 
activities for repair of oxidized pyrimidines. The repair products of this 
excision, including thymidine and hydrouracil are excerted into the urine. 
The formamidopyrimidine DNA glycolylase enzyme (Fpg; mutM) in £. co/i 
repairs the oxidized purines, 8-oxoguanine and 2,6-diamino-4-hydroxy-5-
formamido-pyrimidine and to a lesser extent corresponding adenine 
derivatives (Boiteux et al., 1992). The formamidopyrimidine-DNA 
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Fig. l Products of repair of oxidative DNA damage identified in 
human urine. 
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glycosylase protein appears to repair 8-oxodG in noncoding and actively 
transcribed mammalian DNA sequences with equal efficiency (Bohr et a/., 
1995). The Uvr ABC complex in £. coli repair some oxidative DNA 
lesions by excision of 11-13 nucleotides, including a damaged base such 
as Tg, 8-oxoguanine and 2,6-diamino-4-hydroxy-5-formamidopyrimidine 
as well as abasic sites (Czeczot et al., 1991). Oxidized nucleosides and 
nucleotides from the cellular pools may be incorporated into DNA and 
lead to AT —> GC base substitution mutations in case of 8-oxoGTP 
(Kamiya et al., 1992; Shibutani et al., 1991). In £. coli the mut M and 
mut T repair enzymes cooperate functionally with mut Y, an enzyme 
which removes adenine mis-inserted opposite 8-oxoguanine in DNA (Tajiri 
et a/., 1995). 
Double strand breaks and DNA-protein crosslinks formed by oxygen 
radicals are repaired either by homologous recombination or by non-
homologous end joining (Henle and Linn, 1997). In homologous 
recombination, double strand breaks are initially processed by degrading 
the 5 ends to reveal 3-OH single strand overhangs (Shinohara and Ogawa. 
1995). In mammahan cells, double strand breaks are predominantly 
repaired by non-homologous end joining and it seems that this mode of 
repair is mediated by V(D)J system, which rejoins blunt double strand 
breaks (Jackson and Jeggo, 1995). 
Biological Antioxidant Defenses 
Substances that neutralize the potential ill effects of free radicals are 
generally grouped in the so called antioxidant defense system (Cutler, 
1984). Such a system possesses many substances which are often called 
as antioxidants, free radical scavengers, chain terminators or reductants 
(Heffner and Repine, 1989; Cutler, 1984). Aerobic organisms have potent 
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antioxidant defenses whose role is to neutralize and minimize the 
cytotoxic effects of reactive oxidants. The defenses that directly scavenge 
Og", HgOg and OH are known as primary antioxidant defences. There 
are also secondary antioxidant defenses and consist of repair mechanisms 
which act on biomolecules that have undergone oxidative damage. 
a) Enzymatic antioxidant defenses 
This group includes superoxide dismutase, catalase and glutathione 
peroxidase. 
i) Superoxide dismutase - The enzyme superoxide dismutase (SOD) 
catalyses the dismutation of O2' to H2O2 (Fridovich, 1989). 
SOD 
o,- + o ^ - — > H2O2 + o, 
SOD exists in virtually all Og-respiring organisms, its activity varying 
among the tissues. The highest levels are seen in kidney, liver, adrenal 
gland and spleen. 
ii) Catalase - Catalase is a heme protein that decomposes HX> to O, and 
H^O. 
Catalase 
2 H2O2 > O2 + 2 HgO 
It is present in the cytosol, mitochondria and other organelles but is 
difficult to detect in an extracellular environment. 
iii) Glutathione peroxidase - The selenium based enzyme, glutathione 
peroxidase, reduces H^O^ by catalysing its reaction with the reduced form 
of glutathione (GSH). 
, , ^ « ^ ^ . . Glutathione 
H2O2 + 2 GSH >2 H„0 + GSSG (oxidized glutathione) 
peroxidase 
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Normally, most of the intracellular glutathione is in its reduced form. 
Increased intracellular concentrations of HgOg results in a drop in GSH/ 
GSSG ratio, which serves to detect intracellular oxidative stress (Tribble 
and Jones, 1990). 
b) Non-enzvmatic antioxidant mechanisms 
There are no enzymatic mechanisms to directly protect against OH 
because of its extremely high reactivity and rapid consumption. 
Alternatively, cells possess non-enzymatic antioxidant mechanisms which 
scavenge OH. Some of these scavengers are in hydrophilic phase 
(ascorbate, urate, glutathione) and others in the hpid phase {a-tocopherol 
and P-carotene). Vitamin E (a-tocopherol) is a key OH scavenger and a 
chain breaking antioxidant in biological membranes (Niki et al., 1988). 
It reacts with OH or most commonly with lipid peroxyl radicals (LOO ) to 
form the a-tocopherol radical. Another antioxidant of importance in 
biological membranes is ubiquinol-10 (coenzyme Qj^). Ubiquinoi-10 is as 
efficient as vitamin-E in chain-breaking antioxidant reactions. It is present 
in inner mitochondrial membrane where it also functions as an electron 
carrier in the respiratory chain. 
The various defenses are complementary to each other because they 
metabolize or scavenge different species in different cellular 
compartments. Dietary or pharmacological enhancement of endogenous 
antioxidant defenses may be benefecial in disease or aging processes 
where oxygen radicals are involved. 
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Cancer 
Cancer is the most common term for all malignant tumors. It derives 
from the Latin for crab, 'Cancer' presumably because a cancer adheres to 
any part that it seizes upon in an obstinate manner like the crab. The 
growth of cancers is accompanied by progressive infiltration, invasion and 
destruction of the surrounding tissue. Cancer cells possess an insidious 
property to migrate from the site where they originate and form masses 
at distant sites in the body (Weinberg, 1996). Cancer in all forms are 
causing about 12 percent of deaths throughout the world. In the 
developed countries, cancer is the second leading cause of death, next to 
cardiovascular diseases, accounting for 21 percent (2.5 million) of 
mortality. In developing countries, it ranks third as a cause of death and 
accounts for 9.5 percent (3.8 milUon) of all deaths. According to WHO 
estimates, by the year 2000 the number of cancer deaths may go upto 8 
million annually (The World Health Report, 1997). Among men, the 
leading eight killer sites for cancer are the lungs, stomach, liver, colon-
rectum, oesophagus, mouth-pharynx, prostate and lymphoma. In women, 
they are cancers of the breast, stomach, colon-rectum, cervix, lungs, 
ovary, oesophagus and liver (WHO, The World Health Report, 1998). 
The changes in DNA hke base modifications, rearrangement of DNA 
sequence, miscoding of DNA lesion, gene duplication and the activation of 
oncogenes may involve the initiation of various cancers (Cavenee and 
White, 1995). Mutation in several critical genes can lead to tumors 
(Vogelstein et al., 1989), for example, mutations in the tumor suppressor 
gene, p53 are found in about half of human tumors. Mutations can 
convert proto-oncogenes into carcinogenic oncogenes and studies have 
revealed the presence of human c-or\coger)es with several being active 
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(Marshall, 1985). These genes were found to be mutated, rearranged or 
unusually active in many viral and non-viral tumors. Retroviruses lacking 
c-oncogenes are also oncogenic, giving rise to tumors more slowly than 
those with v-oncogenes (Weiss, 1986). 
Cell division is a critical factor in mutagenesis, because when the cell 
divides a DNA lesion can give rise to a point mutation, deletion or 
translocation (Ames et al., 1993; Cohen et a/., 1991 ; Ames and Gold, 
1990). With increase in cell division, there is increased risk for cancer, 
which can be caused by such diverse agents as increased levels of 
particular hormones (Handerson et a/., 1982), excess calories, chronic 
inflammation or chemicals at doses causing cell division (Cunningham et 
al., 1994; Columbano et a/., 1990; Moalli et al., 1987). 
Alcoholic beverages cause inflammation and cirrhosis of the lung and 
liver (lARC, 1988). Alcohol is an important cause of oral and oesophageal 
cancer (lARC, 1988) and possibly contributes to colorectal cancer 
(Giovannucci et al., 1995). Hepatitis B and C viruses are a major cause 
of chronic inflammation leading to liver cancer, which is one of the most 
common cancers in Asia and Africa (Tabor and Kobayashi, 1992; Yu et 
al., 1991). The mutagenic mold toxin aflatoxin, may cause chronic 
hepatitis infection in liver cancer development (Qian et al., 1994). Some 
cancer chemotherapeutic drugs, particularly the alkylating agents, cause 
malignancies, most commonly leukemias, lymphomas and sarcomas (Ellis 
and Lisher, 1993; Curtis et al., 1992). Potent immuno-suppressive agents 
such as cyclosporin also increase the risk of a variety of cancers (Ryffel. 
1992). 
Epidemiological evidence indicates that avoidance of smoking, 
increased consumption of fruits and vegetables and control of infections 
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will have a major effect in reducing the rates of cancer (Ames et al., 
1995). Other factors include avoidance of intense sun exposure, increase 
in physical activity and reduction of alcohol consumption (Ames et al., 
1995) 
Role of Oxygen Free Radicals in Cancer Development 
Oxygen free radicals are continuously generated in cells exposed to 
an aerobic environment. A number of endogenous and exogenous cancer 
risk factors generate free radicals in viuo (Swartz, 1972). In recent years 
convincing evidence has accumulated indicating that oxygen free radicals 
are indeed a relevant class of carcinogens (Cerutti, 1994; Feig et a/., 
1994; Guyton and Kensler, 1993). Cancer development is now commonly 
recognised as a microevolutionary process that requires the cumulative 
action of multiple events (Klein. 1987). These events can be described in 
a simplified three-stage model : 1) the induction of DNA mutation in a 
somatic cell (initiation), 2) the stimulation of tumorigenic expansion of the 
cell clone (promotion) and 3) the malignant conversion of the tumor into 
cancer (progression). Oxygen free radicals can stimulate cancer 
development at all three stages, initiation (Husain et al., 1994), 
promotion (Nakamura et al., 1988) and progression (Salim, 1993). 
With respect to cancer, DNA is considered to be the most important 
target of ROS (Ames et al., 1995; Feig et al., 1994). Oxidative damage 
to DNA includes a range of specifically oxidised purines and pyrimidines 
as well as alkali labile sites and strand breaks, formed directly or by repair 
processes (Breen and Murphy, 1995; Dizdaroglu, 1994). Floyd et al. 
(1986) supplied the earliest in uitro evidence for a DNA molecular 
alteration by a free radical-generating tumor promoter. They have 
successfully isolated a product of oxidatively damaged DNA, 8-OHdG. To 
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determine whether such radical adducts are involved in carcinogenisis, 
Kasai et al. (1987) carried out an in vivo experiment in which superoxide-
producing KBr03 was administered to animals. The 8-OHdG was detected 
in the kidney, confirming possible tumorigenesis by 0^~ . Additional 
evidence on DNA damage in human fibroblasts was supplied by Kaneko 
and Leadon (1986) who detected the prodution of thymine glycols in DNA 
by the reaction of N-hydroxy-2-napthalamine. Elevated levels of modified 
bases in cancerous tissue may be due to the production of large amounts 
of HgOg, which has been found to be characteristic of human tumor cells 
(Szatrowski and Nathan, 1991). Further, evidence exists that tumor cells 
have abnormal levels and activities of antioxidant enzymes, such as 
superoxide dismutase or catalase, leading to accumulation of 0.^'~ and 
HgO,^  that induces damage to DNA (Olinski et al., 1992). 
In patients with diseases associated with increased risk of cancer, 
including Fanconi anemia, chronic hepatitis, cystic fibrosis and various 
autoimmune diseases, studies indicate an increased rate of oxidative DNA 
damage or in some instances deficient repair (Brown et al., 1995; Hagen 
et al.. 1994; Shimoda et al., 1994; Takeuchi and Morimoto, 1993). 
Human studies support the experimentally based notion of oxidative DNA 
damage as an important mutagenic and carcinogenic factor (Loft and 
Poulsen, 1996). ROS can damage DNA and the division of cells with 
unrepaired or misrepaired damage leads to mutations. The majority of 
mutations induced by ROS appear to involve modification of guanine, 
causing G—>T transversions (Denissenko et al., 1996; Du et al, 1994; 
Colapietro et al., 1993). 
Oxidative stress arises either from the overproduction of ROS or from 
the deficiency of antioxidant defense or repair mechanisms and results in 
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reversible or irreversible tissue injury (Dreher and Junod, 1996). An 
important endogenous cause of chronic oxidative stress is the 
inflammatory response (Cerutti and Trump, 1991). Activated neutrophils 
stimulate mutagenesis in vitro (Weitzman and Gordon, 1990) and 
oxidative stress from chronic inflammation favours cancer development in 
many organs. Cancer induction by chronic inflammation is frequently 
observed in ulcerative colitis (CoUins et al., 1987). Other examples of 
inflammation related carcinogenesis are the mesothehoma caused by 
asbestos deposits (Mossman et al., 1990) and urinary bladder cancer 
induced by Schisttosoma haematobium (Rosin et aJ., 1994). Important 
examples of exogenous causes of oxidative stress and their carcinogenic 
consequences are shown in Table 111. 
A role of ROS in the development of cancer in humans is further 
supported by the abundant presence of oxidative DNA modifications in 
cancer tissue. Thus, the lungs from cancer patients contain 25-75 8-
oxodG per lO'" deoxyguanosine in the apparently normal tissue and two 
to three fold higher values in the tumor, in addition to a whole series of 
other oxidative DNA modifications (Olinski et a/., 1992). Smoking, the 
cause of bronchogenic carcinoma (Doll and Peto, 1981), chronically 
exposes the bronchial epithelium to ROS (Stone and Pryor, 1994). The 
urinary excretion of 8-oxodG and related biomarkers suggests that the 
rate of oxidative DNA modification corresponds upto 10" affected bases 
per cell/day (Loft et al., 1992, and 1993; Shigenaga et al., 1989; 
Cathcart et al., 1984). 
Free radical induced oxidative base damage most likely 
represents an event of considerable importance in the progression of 
breast tumors to the metastatic state and is likely an important etiologic 
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TABLE III 
Major Exogenous Causes of Oxidative Stress Involved in 
Carcinogenesis 
Cause of oxidative 
stress 
Oxygen free 
radicals 
Cancer associated 
with exposure 
Tobacco smoke 
Ultraviolet light 
Fatty acids in 
food 
Iron and copper 
ions 
NO / O H 
•OH , 
organic radicals 
lipid peroxides 
"OH 
Ethanol lipid peroxides 
(Adapted from Dreher and Junod. 1996) 
Bronchogenic 
carcinoma 
melanoma, 
skin cancer 
colorectal and 
.breast cancer 
colorectal cancer 
hepatocellular 
and breast cancer 
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factor (Malins et al., 1993 and 1996). The attack of 'OH on the base 
structure of breast DNA would be expected to result in genetic instability 
causing the activation of nuclear oncogenes and the deregulation of tumor 
suppressor genes such as p53 . One study found a 9-fold increase in 8-
hydroxyguanine, 8-hydroxyadenine and 2 ,6-diamino-4-hydroxy-5-
formamidopyrimidine in DNA from breast carcinoma compared with 
control tissue (Malins and Heimanot, 1991). 
Exposure to ROS and its cellular production are facts of life. ROS can 
cause oxidative DNA damage and protein modifications, damage to tumor 
suppressor genes and enhanced expression of protooncogenes (Cerutti, 
1994; Jackson, 1994) and oxidative stress has been shown to induce 
malignant transformation of cells in culture (Weitzman and Gordon, 
1990). However, the development of human cancer depends on many 
other factors, including the extent of DNA damage, antioxidant defences, 
repair enzymes, the efficiency of removal of oxidized nucleosides before 
they are incorporated into DNA and the cytotoxic effects of ROS in large 
amounts and their growth promoting effects in small amounts (Burdon et 
al., 1995). 
Systemic Lupus Erythematosus 
Systemic lupus erythematosus is an autoimmune disorder with an 
annual incidence of 50 to 70/million and a prevalance of 500/miUion 
population (Klippel, 1997). Major organ system involvement may occur in 
the heart, lungs, kidneys and central nervous system and is responsible 
for most of the mortaHty caused by the disease. The etiology of the 
disorder is incompletely understood (Steinberg et al., 1990 & 1991). It is 
a prototype of spontaneous immune complex disease in which anti-DNA 
antibody complexes deposit in tissue and induce inflammation (Naparstek 
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and Madaio, 1997) . Both genetic and environmental factors are believed 
to contribute to disease (Gourley et a1., 1992). 
The major serological marker of SLE. antibodies to native DNA, 
were distinguished by four different groups as early as 1957 (CepeUini et 
a/., 1957; Meisher and Strassie, 1957; Robbins et al., 1957; Seligmann, 
1957). There are reports of serum anti-dsDNA antibody levels correlating 
with the severity of the renal disease in SLE (Wallace et al., 1993). These 
anti-DNA antibodies found in the sera of patients with SLE are of diverse 
antigenic specificities (Ali et al., 1991; Pollard et al., 1986), which 
include components of DNA, its different conformations including 
modified structures (Alam and Ah, 1992; Hasan et al., 1991). Antigen 
specific and antigen non-specific factors have been implicated in the 
autoantibody production in SLE (Klinman et al., 1990; Datta et al.. 
1987; KHnman; and Steinberg, 1987; Schlomchik et al., 1987). Various 
serological findings suggest that lupus nephritis results from deposition of 
DNA-anti-DNA complexes and subsequent complement mediated tissue 
damage (Nishiya and Hashimoto, 1997; Zouah, 1997; Pisetsky, 1992; 
Emlen et al., 1986). Pankewyez et al. (1987) demonstrated that eluted 
immunoglobulins from the kidney of female MLR-lpr/lpr mice with early 
nephritis was predominantly IgG with antibody activity against DNA. 
These antibodies were also found to be reactive with multiple nucleic 
antigens and non-nucleic antigens like cardiolipin, suggesting that 
polyreactivity might be a distinguishing feature of nephritogenic 
autoantibodies. 
Sequencing of antibody and hybridoma technology have facilitated a 
lot in understanding the features of anti-DNA antibodies which may impart 
pathogenicity and/or allow DNA recognition. Anti-DNA IgG which is 
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cationic in nature produces tissue damage. Putterman et al. (1996) 
reported that charge and affinity may not predict potential for tissue 
damage. Recent studies by Swanson et ai. (1996) indicated that an anti-
ssDNA antibody may be a more potent pathogen compared to a anti-
dsDNA antibody. In addition, it has been suggested, that it is not the 
positive charges which allow pathogenicity but the number of charged 
(positive and negative) residues within the V region which influences this 
property (Ohnishi et al., 1994). 
Apoptosis is an internally programmed cell death pathway 
(frequently initiated by extracellular signals), that regulates both T cell and 
B cell development (Smith et al., 1989; Liu et al., 1989). Accumulating 
evidence suggests that in the normal situation, immature self reactive 
thymocytes undergo apoptotic death (negative selection) upon stimulation 
via the T cell receptors (Von Boehmer, 1986). Emlen et al. (1994) have 
demonstrated that the rate of apoptosis of lymphocytes derived from SLE 
patients was 2.4 times faster than seen in lymphocytes from normal 
controls. The release of intact nucleosomes in excessive amounts during 
the process of apoptosis may thus provide a source of extracellular 
nuclear antigens sufficient to drive an immune response and induce DNA 
antibody production. It has been shown that onset of the autoimmune 
response in murine models of SLE is characterized by the early emergence 
of antibodies that recognize conformational epitopes of the nucleosome 
particles (Burhngame et al., 1993). 
There is increasing evidence to suggest a link between autoimmune 
diseases and cancer (Seda and Alarcon, 1995; Cash and Klippel, 1991; 
Sela and Shoenfeld, 1988) . Patients with SLE have defects in their cellular 
and humoral immune systems. The basic defect in SLE in humans is 
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suggested to be a deficiency in suppressor T cell function, which jeads to 
prohferation and hyper-reactivity of B lymphocytes (Fauci et al., 1978). 
Certain B lymphocytes (CD5* B cells) have a strong tendency to undergo 
oligoclonal or monoclonal prohferation and mahgnant transformation 
(Hayakav^/a and Hardy, 1988). Various findings suggest that cancer 
especially lymphoma and soft tissue sarcoma, is more common in patients 
with SLE than in general population (Patterson et al., 1992). 
The chnical manifestations of SLE are remarkably heterogenous. 
Patients of SLE also exhibit high lipid profiles, which are known to arise 
from renal involvement and a nephrotic state (Appel, 1 9 9 1 ; Attman and 
Alaupovic, 1990). Neurological involvement is also common in SLE 
infhcted individuals (Adelman et al., 1986). More than 60% of patients 
have CNS manifestations and 30-40% have neuromuscular abnormalities 
(Omdal et al., 1989). The major causes of death are directly related to the 
disease and include acute vascular neurologic events, renal failure and 
coronary artery disease (Klippel, 1997). Medication includes non-steroidal 
anti inflammatory drugs for mild form of the disease while high doses of 
corticosteroids and immunosuppressive drugs are needed for chronic SLE 
patients (Blank et al., 1992). 
Role of ROS in SLE 
Hydroxyl radical, a prominent entity of reactive oxygen species, is 
known to modify cellular DNA and has been implicated in several human 
diseases. It has been proposed that in chronic inflammatory diseases such 
as RA and SLE, highly reactive oxygen species released from activated 
phagocytic cells at the site of injury may penetrate cellular membranes 
and react with nuclear DNA (Allan et al., 1988; Lunec et al., 1987; 
Stollar, 1981). ROS play an important role in the development of 
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autoimmune diseases particularly SLE (Ahmad et a/., 1997 ; Alam et a/., 
1993; Ara & Ali, 1993 ; Blount et a/., 1989 & 1990). Oxidative damage 
to DNA in SLE patients has also been reported (Lunec et a/., 1994; 
Bashir et al., 1993) and supports the role of ROS in the etiopathogenesis 
of SLE. The presence of oxidative DNA lesions in SLE was 
immunochemically detected using monoclonal anti-ROS DNA antibody, 
that preferentially recognizes ROS modified epitopes on nucleic acids 
(Ahmad et al., 1998). 
Formation of the altered base 8-OHdG, has been shown to be a very 
sensitive marker of ROS-induced damage (Aruoma et al., 1989; Kasai and 
Nishimura, 1984). The presence of 8-OHdG in the urine of normal 
healthy indiuiduals also affirms that this altered base is a by product of 
normal oxidative metabolism and likely to be the product of a cellular 
repair mechanisms. The very low levels of excreted 8-OHdG in the 
circulating immune complexes of SLE patients, suggests that there is an 
abnormal repair of damaged DNA in these patients (Lunec et al., 1994). 
Resuhs from our laboratory suggests a higher specificity of ROS-poly(G) 
than poly(G) to SLE autoantibodies, which Jmplies that ROS damage may 
lead to formation of modified guanine moieties in DNA and RNA (Garg 
and Ali, 1998). 
Antigenicity of Nucleot ides 
Antibodies may also distinguish between nucleosides and nucleotides. 
With anti-nucleoside antibodies, the large charged phosphate group hinder 
binding, while for anti-nucleotide antibodies it appears to form part of 
determinant (Ungar-Waron, 1967; Halloran and Parker, 1966; Erlanger 
and Beiser, 1964). Seaman et al. (1965) show that antibodies specific for 
poly(A), poly(C) and poly(l) can be produced in rabbits immunized with 
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ribopolymer-MBSA complexes. The results of the immunologic studies 
indicate that nucleotide and DNA-protein conjugates induce the formation 
of antibodies with nucleotide-protcin conjugate (Halloran and Parker, 
1966). Immunization with modified nucleosides or nucleotides conjugated 
to proteins has led to the induction of antibodies (Muller and Rajewsky, 
1980). Nucleosides and nucleotides by themselves are not capable of 
inducing antibodies. So nucleosides are coupled to a carrier protein such 
as BSA by periodate method and then used for immunization. Whereas 
nucleotides/deoxynucleotides can be conjugated to carrier protein by 
carbodiimide method (without cleaving the ribose/deoxyribose ring) 
utihsing the phosphate group present in them. Thus, by retaining the 
intact ribose/deoxyribose ring the resulting antibodies to nucleotide-BSA 
conjugates will be specific for DNA or RNA depending on the type of 
ribose ring present (Chandira Kala and Antony, 1996). Antibodies have 
been raised against deoxy AMP-BSA, deoxy CMP-BSA and GMP-BSA. 
While antibodies to deoxy AMP-BSA, deoxy CMP-BSA bind only to DNA 
(Vaishnav and Antony, 1988, 1989 and 1990), antibodies to GMP-BSA 
predominantly binds to RNA (Chandira Kala and Antony, 1993). 
In human and murine lupus, the most abundant autoantibody 
populations are those reacting with ssDNA (Eilat, 1986; Schwartz and 
Stollar, 1985; Munns et al., 1984; Tan, 1982; Andrezejewski et al, 
1981). These antibodies can be defined in some detail by an ELISA that 
employs not only immobilized ss and dsDNA antigens, but nucleotide 
haptens as well (Weisbart et al., 1983). Generally, such haptens are 
covalentally linked to carrier proteins (e.g. BSA), which by themselves are 
unreactive with autoantibodies. While anti-ssDNA antibodies recognize 
individual base moieties with nucleotides (Ballard and Voss, 1985; Munns 
et al., 1984; Weisbart et al., 1983) one cannot dismiss the possibility 
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that sequence-specific (deoxy) oligonucleotides are responsible for 
antibody interaction with nucleic acids (Deutscher and Kcene. 1988; 
Munns et a/., 1987; Lee et al., 1981). For example, several monoclonal 
anti-ssDNA antibodies have been shown to bind with certain TMP-
containing polynuclotides but not others (Zouali and Stollar, 1986; Ballard 
and Voss, 1985; Lee et al., 1981). Munns, et al. (1987) suggested that 
a significant fraction of anti-ssDNA antibodies in human SLE sera were 
specific for GMP-enrichcd oligonucleotides. 
Objectives of the Present Study 
Systemic lupus erythematosus (SLE) is an autoimmune disorder of 
unknown etiology and is characterized by the presence of circulating anti-
DNA antibodies. Reactive oxygen species have been implicated in a 
number of human degenerative diseases including cancer and SLE. 
In the present study, thymidine 5-monophosphate (TMP) was 
modified with hydroxyl radical generated by irradiation of hydrogen 
peroxide at 254 nm. The ROS-TMP was characterized by UV absorption 
spectra and ion exchange chromatography on DEAE Sephadex A-25 
column. TMP being a hapten was linked with BSA via carbodiimide 
method. TMP-BSA conjugate was modified with hydroxyl radical and 
character ized by UV spec t ra l analysis , Sephadex G-lOO gel 
chromatography, densitometric scanning and agarose gel electrophoresis. 
The antigenicity of ROS-modified TMP-BSA was probed by inducing 
polyclonal antibodies in rabbits. Induced antibodies were characterized for 
their fine antigenic specificity with various nucleic acid polymers. 
Naturally occuring human anti-DNA autoantibodies and the circulating 
antibodies in sera of various cancer patients were also studied for their 
recognition to native and ROS modified TMP-BSA conjugates. 
EXPERIMEMTAL 
32 
MATERIALS 
Thymidine monophosphate , calf thymus DNA, nuclease S I , bovine 
serum albumin, anti-human and anti-rabbit IgG-alkaline phosphatase 
conjugates, ethidium bromide, Coomassie Brilliant Blue G250 and R250, 
Tween 2 0 , F r e u n d ' s complete and incomple te adjuvants, 
polydeoxyribonucleotides and carbodiimide were from Sigma Chemical 
Company, U.S.A. Synthetic polynucleotides, Sepharose 4B, DEAE 
Sephadex A-25, Sephadex G-lOO, Ficoll 400 were obtained from 
Pharmacia Fine Chemicals , Sweden. Folin-Ciocalteu reagent, p-
nitrophenyl phosphate and Blue Dextran 2000 were purchased from 
Centre for Biochemical Technology, New Delhi. 
Polystyrene microtitre flat bottom ELISA plates having 96 wells (7mm 
diameter) were p u r c h a s e d from Nunc, Denmark . Acrylamide, 
bisacrylamide, ammonium persulphate, N,N,N',N'-tetramethylethylene 
diamine (TEMED) were from Bio-Rad Laboratories, U.S.A. EDTA 
(disodium salt), hydrogen peroxide, isoamyl alcohol, chloroform were from 
Qualigens, India. Diphenylamine and ethanol were chemically pure. All 
other chemicals were of highest analytical grade available. 
Equipment 
ELISA microplate reader MR-600 (Dynatech, U.S.A.), ELISA 
microplate washer (Denley, England), ELICO pH meter model Ll-120, 
Shimadzu UV-240 spectrophotometer equipped with thermo-programmer 
and controller unit, gel scanner GSC-3A. ultraviolet lamp having 
maximum emission at 254 nm (Vilber Lourmat, France), Avanti 30 table 
top high speed centrifuge (Beckman, U.S.A.), Polyacrylamide gel 
electrophoresis assembly (Bio-Rad, U.S.A.), UV trans-illuminator (Vilber 
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Lourmat, France), Agarose gel electrophoresis assembly GNA-100 
(Pharmacia, Sweden), Beckman ultracentrifuge were the major 
equipments used in this study. 
Sera Spec imens 
SLE sera were obtained from outdoor and indoor patients of the 
Department of Medicine, All India Institute of Medical Sciences, New 
Delhi. The SLE sera collected, showed high titre anti-DNA antibodies and 
fulfilled the American College of Rheumatology criteria for the diagnosis 
of SLE (Arnett et al., 1988). The sera of cancer patients were collected 
from Department of Radiotherapy, J.N. Medical College, A.M.U., AHgarh. 
Complement was inactivated at 56 °C for 30 minutes and stored at -80"C 
with 0 . 1 % sodium azide. 
METHODS 
Purification of DNA 
Commercially available, highly polymerized calf thymus DNA was 
purified free of proteins and single stranded regions (Ah et al., 1985). 
DNA was dissolved in 0.1 X SSC (15 mM sodium citrate and 150 mM 
sodium chloride), pH 7 .3 . Solutions of DNA (2 mg/ml) was mixed with 
equal volume of chloroform-isoamyl alcohol (24:1) in a stoppered 
cylinder and extracted gently for 1 hr. The DNA present in the aqueous 
layer was separated from the organic layer and re-extracted with 
chloroform-isoamyl alcohol. The DNA was precipitated with two volumes 
of cold 95% ethanol and collected on a glass rod. Traces of water was 
removed by rinsing the rod with ethanol and DNA dried by pressing 
against the wall of the container. The DNA was then dissolved in 30 mM 
acetate buffer, pH 5.0 containing 30 mM zinc chloride and treated with 
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nuclease SI (150 units/mg DNA) at 37°C for 30 min to remove single 
stranded regions. The reaction was terminated by adding one-tenth 
volume of 200 mM EDTA, pH 8.0. The purified DNA was extracted twice 
with chloroform-isoamyl-alcohol and finally precipitated with 9 5 % 
ethanol. The precipitate was dissolved in PBS (10 mM sodium-phosphate, 
containing 150 mM NaCl), pH 7.4. 
Estimation of DNA by Diphenylamine 
Colorimetric estimation of DNA was carried out by the method of 
Burton (1956) using diphenylamine reagent. 
(a) Preparation of diphenylamine reagent 
Recrystallized diphenylamine (750 mg) was dissolved in 50 ml of 
glacial acetic acid containing 0.75 ml concentrated sulphuric acid. The 
reagent was prepared immediately before use. 
(b) Procedure 
To varying amounts of DNA in 1.0 ml of IN perchloric acid was 
mixed and incubated at 70**C in water bath for 15 min. One hundred 
microlitre of 5.43 mM acetaldehyde was added followed by 2.0 ml of 
diphenylamine reagent. The contents were mixed and allowed to stand at 
room temperature for 16-20 hrs. Absorbance was read at 600 nm and the 
concentration of DNA in unknown samples was determined from the 
standard plot of purified calf thymus DNA. 
Protein Estimation by Bradford Method 
Protein was estimated by the method of Bradford (1976). This assay 
is based on colour change that occurs when Coomassie Brilliant Blue 
G250, in acidic solution, binds strongly to protein hydrophobically and at 
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positively charged groups. In the environment of these positively charged 
groups, protonation is suppressed and a blue colour is observed (\^^ 595 nm). 
(a) Dye preparation 
Coomassie Brilliant Blue G250 (100 mg) was dissolved thoroughly in 
50 ml of 95% ethanol. One hundred ml of 85% (v/v) orthophosphoric acid 
was added to this solution. The resulting solution was diluted to a final 
volume of 1 litre. On every use the dye solution was filtered, to remove 
undissolved particles. 
(b) Procedure 
Solutions containing 10-100 pg protein in a volume of upto 0.1 ml 
was pipetted into test tubes. The volume was adjusted to 1.0 ml with 
appropriate buffer. Five ml of dye solution was added and the contents 
were vortexed. The absorbance was read at 5 9 5 nm after 2 min and 
before 1 hr against a reagent blank prepared from 0.1 ml of buffer and 
5.0 ml of dye solution. 
ROS Modification of TMP 
Aqueous solution of native TMP (0.31 mM) in PBS, pH 7.4 was 
irradiated under 254 nm light for 30 min at room temperature in the 
presence of hydrogen peroxide (3.10 mM). Native TMP samples exposed 
to hydrogen peroxide or UV light alone were used as corresponding 
controls. 
Spectroscopic Analys is 
The ultraviolet spectra of modified and unmodified TMP conjugate 
were recorded in the wavelength range of 200-400 nm on Shimadzu UV-
240 spectrophotometer. 
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Preparation of the Antigen 
The hapten-protein conjugate was prepared by the carbodiimide 
conjugation procedure of Halloran and Parker (1966). BSA (19 mg) and 
thymidine 5'-monophosphate (50 mg) were dissolved in 5.0 ml of distilled 
water. The pH was adjusted to 7.5 with 0.5 M NaOH, and ethyl 
((dimethylamino) propyl) carbodiimide (20 mg) was added. The reaction 
mixture was incubated in the dark at room temperature for 24 hrs. The 
solution was then dialyzed extensively against 10 mM Tris-HCl buffer. pH 
7.6, followed by extensive dialysis against distilled water. 
The ultravoilet spectra of native TMP, BSA and TMP-BSA conjugate 
were recorded in the range of 200-400 on Shimadzu UV-240 
spectrophotometer. 
Polyacrylamide Gel Electrophoresis 
BSA and TMP-BSA conjugate were subjected to polyacrylamide slab 
gel electrophoresis according to the method of Laemmli (1970). 
(a) Stock so lut ions 
(i) Acri;lamide-bisacrylamide (30:0.8): 
Prepared by dissolving in distilled water 30.Og of acrylamide and 0.8 
g of bisacrylamide in a total volume of 100.0 ml. The solution was stored 
at 4°C in a brown bottle. 
(ii) TEMED: Used as supplied. 
(iii) Ammonium persulphate (1.5% w/v): 
0.15 g of ammonium persulphate was dissolved in 10.0 ml water. 
The solution was made fresh just before use. 
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(iv) Resolving gel buffer (3M Tris-HCl, pH 8.8): 
Prepared by dissolving 36.Og Tris in 48 .0 ml of 1 N HCl. The 
contents were mixed thoroughly, pH brought to 8.8 and final volume 
made upto 100.0 ml with distilled water. 
(v) Stacking gel buffer (0.5 M Tris-HCl, pH 6.8): 
Tris (6.05g) was dissolved in 40 .0 ml distilled water, titrated to pH 
6.8 with IN HCl and volume made upto 100.0 ml with distilled water. 
(vi) Reservoir buffer (25 mM Tris, 192 mM gl{;cine): 
3.03 g Tris and 14.4 g glycine were dissolved in distilled water and 
final volume made upto one litre. 
(b) Recipe for 7 . 5 % Resolving gel 
(c) 
Acylamide-biasacrylamide 
Resolving gel buffer 
1.5% Ammonium persulphate 
Distilled water 
TEMED 
Recipe fo 2 . 5 % stacking gel 
Acrylamide-bisacrylamide 
Stacking gel buffer 
1.5% Ammonium persulphate 
Distilled water 
TEMED 
7.5 ml 
3.75 ml 
1.5 ml 
16.95 ml 
15.0 yl 
2.5 ml 
5.0 ml 
1.0 ml 
11.3 ml 
15.0 yl 
(d) Procedure 
The resolving gel mixture was prepared by mixing the components in 
the appropriate volumes as listed above and poured into the space 
between the glass plates leaving sufficient space (about 3.5 cm) at the 
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top for the stacking gel. After the polymerization of separating gel. 
stacking gel mixture was poured and allowed to solidify. Samples 
containing 10% glycerol and 0.002% bromophenol blue were applied and 
electrophoresis was carried out at 24 mA for 2-3 hr. Staining of the gel 
was achieved with 0 . 1 % Coomassie Brilliant Blue R 250 (in 25% 
isopropanol and 10% glacial acetic acid) and the gel was destained using 
a mixture of 10% glacial acetic acid and 30% methanol. 
ROS-Modification of TMP-BSA Conjugate 
Aqueous solution of TMP-BSA conjugate (6.20 mM) in PBS. pH 7.4 
was irradiated under 254 nm light for 30 min. at room temperature in 
the presence of hydrogen peroxide (62 mM). Excess of hydrogen peroxide 
was removed by extensive dialysis against PBS, pH 7.4. The ultraviolet 
spectra of TMP and ROS-modified TMP were recorded. 
Absorption-Temperature Scan 
Thermal denaturation analysis of native and ROS-modified conjugates 
were accomplished in a Shimadzu UV-240 spectrophotometer coupled 
with a temperature programmer and controller assembly. Native and ROS-
modified TMP-BSA conjugates were subjected to heat denaturation 
(Hasan and AH, 1990). Samples were melted from 30"C to 95"C at a rate 
of 1.5"C/min after 10 min equilibration at 30"C. The change in 
absorbance at A.^^^^^  was recorded with increasing t e m p e r a t u r e . 
Simultaneously, UV spectra were also recorded at 30"C and 95"C in the 
same wavelength range. 
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Sephadex G-lOO Gel Chromatography 
Gel filtration was performed on Sephadex G-lOO column. Five gm of 
gel was swollen in distilled water for 5 hr in a boiling water bath. The 
degassed gel slurry was poured into the column (42 cm x 1 cm) and left 
overnight at room temperature to settle under gravity. The flow rate was 
increased gradually and adjusted to 20 ml/hr. Uniform packing of column 
was checked by passing 0.2% (w/v) solution of Blue Dextran 2000 . The 
column was equilibrated with PBS, pH 7.4. 
One ml each of native and ROS-TMP-BSA conjugates were applied 
separately onto the column. The sample was allowed to percolate through 
the upper surface of the gel. The column was connected to a reservoir 
containing equilibrating buffer. Fractions of 3.0 ml were collected and 
absorbance monitored at 269 nm. 
Densitotnetric Scanning 
Samples of native and ROS-modified conjugates were subjected to 
polyacrylamide gel e lec t rophores is on 7 .5% native gel. After 
electrophoresis, the lanes each of native and ROS-modified conjugates 
were cut and scanned on gel scanner GSC-3A of Shimadzu U\/-240 
spectrophotometer. Gel was scanned at the rate of 10 mm/min and the 
spectra was recorded simultaneously at a fixed wavelength of 269 nm. 
Agarose Gel Electrophores is 
1% agarose in 30 ml TAE, pH 7.9, was dissolved by heating in 
boiling water bath. The solution was allowed to cool at 50"C and poured 
onto the gel tray and left at room temperature for complete solidification. 
Samples mixed with one-tenth volume of stop mix dye (30% Ficoll. 
0 .025% xylene cyanole FF in gel buffer), was loaded in the wells of the 
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submerged gel and electrophoressed for 2 hr at 30 mA. The gels were 
stained with Coornassie Brilliant Blue R 250 and destained in tap water. 
Immunization Schedule 
Female rabbits (8-12 months, weight 1-1.5 kg) were immunized with 
native and ROS-modified TMP-BSA conjugates. The immunizing antigen 
(100 pg/rabbit) was emulsified with equal volume of Freund's complete 
adjuvant (FCA) for the first injection given subcutaneously at multiple 
sites. Subsequent injections were given in incomplete adjuvant (IFA) 
intramuscularly. Each animal received a total of 700 yg of antigen during 
the course of seven injections. Booster dose was administered after a 
fortnight from the last injection. Blood was collected by cardiac puncture 
and serum separated. The separated serum was decomplemented by 
heating at 56"C for 30 min. Preimmune sera were collected before 
immunization. The sera were stored in small aliquots at -80"C with 0 .1% 
sodium azide as preservative. 
Isolation of IgG by Protein A-Sepharose CL-4B 
Serum IgG was isolated by affinity chromatography on protein A-
Sepharose CL-4B column. 0.5 ml serum diluted with equal volume of 
PBS, pH 7.4 was applied to column (15 cm x 0.9 cm) equilibrated with 
the same buffer. The wash through was recycled 2-3 times. Unbound IgG 
was removed by extensive washing with PBS, pH 7.4. The bound IgG was 
eluted with 0.58% acetic acid in 0.85% sodium chloride (Coding. 1976) 
and neutralized with 1 ml of 1 M Tris-HCI, pH 8.5. Three ml fractions 
were collected and read at 280 nm. The concentration was determined 
considering 1.4 O.D.^ p(, =1.0 mg IgG/ml. The IgG was then dialyzed 
against PBS, pH 7.4 and stored at -SO"C with 0 . 1 % sodium azide. 
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Immunological Techniques 
Immune, SLE and cancer sera were tested for antibodies by 
immunodiffusion, counterimmunoelectrophoresis and enzyme linked 
immunosorbent assay. 
(a) immunodiffusion 
Immunodiffusion (ID) was carried out by Ouchterlony double 
immunodiffusion system using glass petri dishes as described by Tan et a). 
(1966). Six ml of 0.4% molten agarose in PBS, pH 7.4 containing O.l'i^ n 
sodium azide was poured onto glass petri dishes and allowed to solidify at 
room temperature and then kept at 4"C for 4 hrs. Wells 5 mm in 
diameter separated by 8 mm in distance, were cut into hardened gel. 
Antigen and antibody were loaded and kept in moist chamber for 24-48 
hrs. The petri dishes were washed with 5% sodium citrate to remove non-
specific precipitin hnes, if any. The precipitin lines were analyzed visually 
and photographed. 
(b) Counterimmunoelectrophoresis 
Counterimmunoelectrophoresis was performed by the method of 
Kurata and Tan (1976). Molten agarose (0.6%) in 25 mM barbital buffer. 
pH 8.4, containing 0 . 1 % sodium azide was poured onto 2.5 mm thick 
glass slides (7.5 cm x 2.5 cm) and allowed to harden at room temperature 
and then at 4^C. Wells each 3 mm in diameter were cut and loaded with 
antigen and antibodies (in anodal and cathodal wells, respectively). The 
slides were then electrophoressed for 45-60 min in 50 mM barbital buffer. 
pH 8.4 with a current of 3-4 mA per slide. Non-specific precipitin lines 
were removed with 5% sodium citrate. 
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(c) Enzyme linked Immunosorbent Assay (ELISA) 
ELISA was performed using polystyrene (96 wells) flat bottom 
microtitrc plates as described by Aotsuka et al. (1979). 
(i) Buffers and substrate 
Tris buffered saline (TBS) 
10 mM Tris, 150 mM sodium chloride, pH 7.4. 
Tris buffered saline-Tween 20 (TBS-T) 
20 mM Tris, 144 mM sodium chloride, 2.68 mM potassium chloride 
(KCl), pH 7.4, containing 500 i^L Twecn-20/L 
Carbonate-bicarbor)ate buffer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, 2 mM magnesium 
chloride, pH 9.6. 
Substrate 
500 pg p-nitrophenyl phosphate/ml of carbonate-bicarbonate buffer. 
(ii) Procedure 
Polystyrene microtitre plates were coated with 100 pi of antigen (2.5 
pg/ml in TBS, pH 7.4) for 2 hr at room temperature and overnight at 
4"C. Unbound antigen was removed by washing thrice with TBS-T. 
Unoccupied sites were blocked with 200 pL of 1.5% BSA in TBS for 4-
6 hr at room temperature. The plates were washed once with TBS-T. The 
antibody 1:100 diluted in TBS was coated in each well. After incubating 
the plates for 2 hrs. at room temperature and at 4"C overnight, the plate 
was extensively washed with TBS-T. The bound antibodies were then 
assayed by an appropriate anti-immunoglobuHn alkaline phosphatase 
conjugate using p-nitrophenyl phosphate as substrate. The plates were 
incubated at 37"C for 1 hr and then read at 410 nm. Each .sample was 
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coated in duplicate and the results were expressed as a mean of A,^  ,-
A 
rontrol' 
(d) Competition ELISA 
The antibody specificity was determined by competition ELISA 
(Hasan et al., 1991). Varying amounts of inhibitors (0-20 yg/ml) were 
incubated with a constant amount of antibody for 2 hrs. at room 
temperature and overnight at 4°C. The resulting immune complex was 
coated in wells instead of the serum IgG. The remaining steps were the 
same as in direct binding ELISA. The results were expressed as percent 
inhibition. 
irihibitGcl 
Percent inhibition = 1 X 100 
uriirihibitC'J 
i^nhibited ~ Absorbance at 20 pg/ml inhibitor concentration 
u^ninhibitrd ~ Absorbance at zero inhibitor concentration. 
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Formation of ROS-TMP and its Characterization 
A solution of thymidine monophosphate in PBS, pH 7.4 was 
modified with reactive oxygen species. UV irradiation (254 nm) in the 
presence of hydrogen peroxide is known to generate hydroxyl radical. The 
UV absorption spec t ra was recorded on a Shimadzu UV-240 
spectrophotometer in the wavelength range of 200 to 400 nm. Figure 2 
shows the UV absorption spectra of TMP irradiated for 15 and 30 
minutes, indicated a loss in the characteristic absorption pattern of TMP 
as a result of damage caused by hydroxyl radical. The perturbations 
incurred on TMP as a consequence of ROS modification were also 
analysed by UV difference spectroscopic scanning (Fig. 3). The spectral 
curve for TMP with respect to buffer (PBS, pH 7.4) showed ?v^_^^ at 267 
nm, characteristic oi native TMP. The difference spectra of ROS-TMP,with 
reference to TMP exhibited a strong negative trough having a broad peak 
between 282 to 255 nm and a complete disappearence of positive peak 
at 267 nm. 
Conjugation of TMP with BSA 
TMP was linked with BSA through carbodiimide method of 
conjugation. The UV spectra shows a slight bathochromic shift in TMP-
BSA conjugate when compared with native TMP (Fig. 4). Carbodiimides. 
which contain secondary and tertiary amine groups, react with nucleotides 
altering its structure which rendered it more immunogenic. The formation 
of TMP-BSA conjugate was ascertained by 7.5'Kn PAGE. The gel profile 
indicated the formation of high molecular weight band of complex with 
increasing concentration of TMP-BSA conjugate (Fig. 5). 
t * D 
300 
WAVELENGTH ( n m ) 
400 
Fig.2 UV absorption spectra of native TMP (—4 irradiated for 15 
min (—) and 30 min ( ) under UV light in presence oi 
hydrogen peroxide. TMP alone irradiated under UV light 
{—), H^O^ alone (—) and unirradiated TMP + H^O.^  samples (—•) 
served as controls. 
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WAVELENGTH ( n m ) 
4 0 0 
Fig. UV difference spectra of native TMP ( — 
to buffer (PBS, 7.4) and ROS-TMP ( ) 
native TMP. 
—) with reference 
with reference to 
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200 300 
WAVE LENGTH (nm) 
AOO 
Fig 4 The TMP-BSA conjugate was prepared by carbodiimide 
method of conjugation UV spectra of TMP-BSA conjugate 
(—). TMP alone (-—), BSA alone (• ) and TMP-BSA 
without carbodiimide ( ) 
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1 2 3 4 
Fig.5 Polyacrylamide gel electrophoresis (7.5"'n) of TMP-BSA 
conjugate with stacking gel {2.5%). Lane 1 (BSA). lanes 2-
4 show increasing concentration of TMP-BSA conjugate 
(60 .90 and 120 pg. respectively). 
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ROS-Modiffication of TMP-BSA Conjugate 
TMP-BSA conjugate was modified with hydroxyl radical. The 
irradiated sample was dialyzed against PBS to remove excess of hydrogen 
peroxide. Figure 6 shows the UV absorption spectra of native and 
modified conjugate. TMP-BSA conjugate gave a sharp peak at A.,_^^ (269 
nm), whereas ROS-modified conjugate indicated an appreciable amount of 
hypochromicity, with a shoulder around X.^^^ ^^ . This loss in characteristic 
absorption pattern is due to degradation of conjugate incurred as a result 
of hydroxyl radical modification. The perturbations occurring on TMP-
BSA conjugate as a consequence of ROS-modification were also analysed 
by UV difference spectroscopy (Fig. 7). Difference spectrum of ROS-
modified conjugate revealed an appreciable negative inversion absorption 
with respect to native conjugate. 
Thermal Transition Studies 
UV spectra of native and modified conjugates were recorded at 30"C 
and 95°C. The UV spectrum of TMP-BSA conjugate at 95"C did not show 
any appreciable deviation from the spectral curve recorded at SO '^C (Fig. 
8). However, distinct hyperchromicity was observed in case of ROS-
modified TMP-BSA conjugate at 95°C as compared to the spectrum at 
SO^C (Fig. 9). This hyperchromicity could be due to some structural and 
conformational changes in TMP-BSA conjugate incurred after ROS-
modification. 
Sephadex-G 1 0 0 Gel Filtration 
Equal concentration of both native and ROS-TMP-BSA conjugate was 
apphed on Sephadex G-lOO column. Native TMP-BSA conjugate appeared 
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WAVELENGTH(nm) 
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Fig.6 Ultraviolet absorption spectra of TMP-BSA conjugate (—). 
ROS-TMP-BSA conjugate (—) and TMP alone (—). 
31 
-0.5 
200 3 0 0 
WAVELENGTH ( n m ) 
400 
Fig.7 UV difference spectra of TMP-BSA conjugate ( ) against 
buffer (PBS. 7.4) as control and ROS-TMP-BSA conjugate 
( ) with reference to TMP-BSA conjugate. 
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Fig.8 UV absorption spectra 
{ —) and 95"C (—). 
of TMP-BSA conjugate at 30 C 
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WAVELENGTH(nm) 
400 
Fig.9 UV absorption spectra of ROS-TMP-BSA 
30"C (—) and 95"C (—). 
conjugate at 
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in small peaks alongwith a sharp symmetrical peak at fraction no. 3 1 , 
whereas ROS-TMP-BSA conjugate indicated a degraded product with a 
hypochromic shift corresponding to fraction no. 31 (Fig. 10). Formation 
of low molecular weight species from high molecular weight complex 
reiterates the modification of TMP-BSA conjugate by hydroxyl radical. 
Densitometric Scanning 
TMP-BSA and ROS-modified conjugate were resolved on 7.5% 
polyacrylamide gel and were subsequently subjected to densitometric 
scanning at 269 nm (Fig. 11). ROS-TMP-BSA conjugate showed a single 
peak of low intensity as compared to TMP-BSA conjugate. The data 
indicates that considerable amount of TMP-BSA conjugate has been 
modified by hydroxyl radical, which in turn leads to strand breaks and thus 
formation of low molecular weight species. 
Agarose Gel Eletrophoresis 
Both the native and ROS-modified TMP-BSA conjugates were 
resolved on a 1% agarose gel. As evident from figure 12, modified 
conjugate exhibits low intensity as compared to its native form which 
might be due to the formation of low molecular weight species, as a result 
of oxidative damage to the complex. 
Antigenicity of Native and ROS-Modified TMP 
(a) Antibodies against TMP and ROS-TMP 
The antigenicity of native and ROS-TMP was probed by inducing 
antibodies in rabbits. The production of antibodies against TMP and ROS-
TMP could not be elicited as revealed by direct binding and inhibition 
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Fig. 10 Fractionation of TMP-BSA conjugate ( O ) and ROS-TMP-
BSA conjugate ( A ) on Sephadex G-lOO gel filtration 
column. 
LENGTHOF G £ L ( c n i ) 
Fig. 11 Densitometric scanning of TMP-BSA conjugate (—) and 
ROS-TMP-BSA conjugate (—) a f t e r 7 . 5 % nat ive 
polyacryamide gel electrophoresis. 
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1 ^ 3 4-
Fig . l2 Agarose gel electrophoresis of TMP-BSA conjugate and 
ROS-moditied conjugate. Staining was performed with 
Coomassie Brilliant Blue R-250. TMP-BSA conjugate, lanes 
1 {20pg) and 2 (40pg) ROS-TMP-BSA conjugate, lanes ." 
(20vig) and 4 (40pg). 
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ELISA results. In order to make TMP immunogenic, it was linked to a 
carrier protein (BSA) and then modified with hydroxyl radical. 
(b) Antibodies against TMP-BSA and ROS-TMP-BSA conjugates 
The antibodies raised against TMP-BSA and ROS-TMP-BSA 
conjugates were found to be precipitating as detected by immunodiffusion 
and counterimmunoelectrophoresis (Fig. 13 and 14). The antiserum 
showed a titre of 1:12800 by direct binding ELISA on plates coated with 
TMP-BSA conjugate. Preimmune serum showed negligible binding (Fig. 
15). The specificity of induced antibodies was determined by competition 
ELISA. Induced antibodies were found to be highly specific for its 
immunogen. A maximum of 95% inhibition of antibody binding was 
observed. Fifty percent inhibition was observed at an inhibitor 
concentration of 2.0 pg/ml (Fig. 16). Anti-ROS-TMP-BSA antibodies 
showed a titre of 1:12800 by direct binding ELISA on plates coated with 
ROS-TMP-BSA conjugate. Preimmune serum showed negligible binding 
(Fig. 17). In competition inhibition assay, a maximum of 92% inhibition 
was observed and 50% inhibition was achieved with 2.5 pg/ml (Fig. 18). 
(c) Purification and characterization of immune IgG 
Immunoglobulin G against TMP-BSA and ROS-TMP-BSA conjugate 
were isolated from the respective sera by affinity chromatography on 
Protein A-Sepharose CL-4B column (Fig. 19 and 20). IgG from 
preimmune sera was also purified (Fig. 21). The purity of IgG was 
ascertained by SDS-PAGE under non-reducing conditions (inset of Fig. 19-
21). As seen, purified IgG migrated as a single band. A high magnitude 
of binding of the purified anti-TMP-BSA conjugate and ROS-modified 
conjugate with respective immunogen was exhibited by direct binding 
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(CL) 
(b; 
Fig. 13 Immunodiffusion of anti-TMP-BSA conjugate antibodies with 
TMP-BSA conjugate (a) and anti-ROS-TMP-BSA conjugate 
antibodies with ROS-TMP-BSA conjugate (b) 
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(a:) 
Cb) 
Fig. 14 Counterimmunoelectrophoresis of anti-TMP-BSA conjugate 
antibodies with TMP-BSA conjugate (a) and anti-ROS-TMP-
BSA conjugate (b). Electrophoresis was performed on 0 6% 
agarose gel for 2 hr at 140 V. 
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Fig. 15 Direct binding ELISA of TMP-BSA conjugate with pre-
immune { A ) and immune sera ( A )• The microtitre plates 
were coated with TMP-BSA conjugate (10 )jg/ml). 
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Fig. 16 Inhibition ELISA of immune sera with TMP-BSA conjugate. 
The microtitre plates were coated with TMP-BSA conjugate 
(10 vig/ml). 
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Fig. 17 Direct binding ELISA of ROS-TMP-BSA conjugate with 
preimmune ( J^ ) and immune sera ( A ) The microtitre 
plates were coated with TMP-BSA conjugate (10 ng/ml). 
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Fig. 18 Inhibition ELISA of immune sera with ROS-TMP-BSA 
conjugate ( O )• The microtitre plates were coated with 
TMP-BSA conjugate (10 yg/ml). 
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Fig. 19 Elution profile of anti-TMP-BSA conjugate IgG on Protein 
A-Sepharose CL-4B column. Inset: SDS-PAGE of purified 
IgG on 7.5% polyacrylamide gel. 
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Fig 20 Elution profile of anti-ROS-TMP-BSA conjugate IgG on 
Protein A-Sepharose CL-4B column Inset SDS-PAGE of 
purified IgG on 7 5% polyacrylamide gel 
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Fig.21 Elution profile of preimmune IgG on Protein A-Sepharose 
CL-4B column. Inset: SDS-PAGE of purified IgG on 7.5% 
polyacrylamide gel. 
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ELISA (Fig. 22 and 23). No appreciable binding was observed in case of 
preimmune IgG. The specificity of the purified IgG was evaluated by 
competitive inhibition assays. A maximum of 95% (at 10 pg/ml) inhibition 
of anti-TMP-BSA conjugate IgG and 98% of anti ROS-TMP-BSA conjugate 
with respective immunogens (used as inhibitors) was observed (Fig. 24). 
Fifty percent inhibition was achieved at an inhibitor concentration of 0.3 
Hg/ml in case of TMP-BSA conjugate while 0.5 pg/ml was required for 
corresponding ROS-modified conjugate. 
Immuno-crossreactivity of Anti-TMP-BSA Conjugate Antibodies 
The antigenic specificity of the induced anti-TMP-BSA conjugate 
antibodies was characterized by competition inhibition assay using nucleic 
acids, polynucleotides and bases as inhibitors. TMP-BSA conjugate 
showed an inhibition of 42% in the antibody binding. Native calf thymus 
DNA and its modified conformer (ROS-DNA) showed moderate inhibitions 
of 48% and 33%, respectively (Fig. 25). TMP, thymidine and thymine 
showed lower inhibitions of 28%, 16% and 21%, respectively. Their ROS-
modified forms were also used as inhibitors. ROS-TMP showed inhibition 
of 69% at 20 ng/ml. Fifty percent inhibition of antigen-antibody 
interaction was obtained with 15 jag/ml. ROS-thymine showed inhibitions 
of 56% (50% inhibition at 18 pg/ml) and 82% (50% inhibition at 5.5 ng / 
ml), respectively (Fig. 26). Simiharly ROS-guanine and ROS-adenine 
showed higher inhibition of 6 1 % and 59%, respectively. Native adenine 
and guanine showed 29% and 46% inhibitions (Fig. 27). Among 
homopolymers, poly(G) and its ROS-modified form showed moderate 
inhibitions of 45% and 40%, while poly(l) was found to be non-inhibitory 
(Fig. 28). 
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Fig.22 Direct binding ELISA of preimmune ( A ) and immune 
IgG ( A ) with TMP-BSA conjugate. The microti tre plates 
were coated with TMP-BSA conjugate (10 jjg/ml). 
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Fig.23 Direct binding ELISA of preimmune ( A ) and immune 
IgG ( A ) with ROS-TMP-BSA conjugate. The microtitre 
plates were coated with TMP-BSA conjugate (10 |ig/ml). 
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Fig.24 Inhibition of anti-TMP-BSA IgG and anti-ROS-TMP-BSA IgG 
binding to TMP-BSA conjugate ( O ) and ROS-TMP-BSA 
conjugate ( A ) . The competitors were TMP-BSA conjugate 
and ROS-TMP-BSA conjugate respectively. 
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Fig.25 Inhibition of anti-TMP-BSA conjugate IgG binding to TMP-
BSA conjugate . The compet i to rs were ROS-TMP-BSA 
conjugate ( Q ) , native ctDNA ( A ) and ROS-DNA ( A ) . 
The microtitre plates were coated with TMP-BSA conjugate 
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Fig.26 Inhibition of anti-TMP-BSA conjugate IgG binding to TMP-
BSA conjugate. The competitors were TMP ( O ) - ROS-TMP 
\ ^ )f thymidine { A ), ROS-thymidine ( 0 ). thymine 
( ^ ) and ROS-thymine ( -^ ). The microtitre plates were 
coated with TMP-BSA conjugate (10 pg/ml) . 
74 
UJ 
o 
flC 
III Q, 
20 
40 
6 0 
80 
100 
0.01 0.1 10 100 
INHIBITOR CONCENTRATION ( jug/ml) 
Fig.27 Inhibition of anti-TMP-BSA conjugate IgG binding to TMP-
BSA conjugate. The competitors were guanine ( O )• ROS-
guanine ( A )- adenine ( A ) and ROS-adenine ( 0 ). 
The microti tre plates were coated with TMP-BSA conjugate 
(10 vig/ml). 
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To further study the structural determinants recognized by anti-TMP-
BSA conjugate antibodies, their interaction with various synthetic 
polydeoxynucleotides was examined. Poly(dA-dT).poly (dA-dT) exhibited a 
moderate inhibition of 36%. Poly(dA-dU).poly(dA-dU) and poly(A).poly(U) 
showed negligible inhibitions (Fig. 28). Table IV summarizes the binding 
characteristics of anti-TMP-BSA conjugate antibodies. 
Immuno-crossreact iv i ty of Anti-ROS-TMP-BSA Conjugate 
Antibodies 
Antigenic specificity of anti-ROS-TMP-BSA antibodies was also 
characterized by competition inhibition assay. When TMP-BSA conjugate 
was used as an inhibitor, a maximum of 89% inhibition in the antibody 
binding was observed (Fig. 29). The concentration of TMP-BSA conjugate 
required to inhibit 50% antibody activity was 0.2 vig/ml. Native TMP and 
thymidine showed inhibition of 39% and 23% while their ROS-modified 
forms showed a maximum inhibition to an extent of 86% and 56%. 
respectively (Fig. 29). ROS-modified forms of thymine, guanine and 
adenine showed negligible inhibition. Guanine showed inhibition of 55%) 
(Fig. 30). Calf thymus DNA, cytosine and ROS-cytosine were found to be 
non-inhibitory (Fig. 31). Poly(G) gave a moderate inhibition of 38%, while 
ROS-poly(G) was found to inhibit to a maximum of 5 3 % (Fig. 31). 
The specificity of the anti-ROS-TMP-BSA antibodies was also 
assessed using synthetic polynucleotides. PoIy(dA-dU).poly(dA-dU) and 
poly(dl-dC).poly(dI-dC) showed a maximum inhibition of 35% (Fig. 32). 
Poly(dA-dT).poly(dA-dT) and poly(A).poly(U) showed negligible inhibitions 
(Fig. 32). Table V gives a summary of the binding characteristics of anti-
ROS-TMP-BSA conjugate antibodies. 
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Fig.28 Inhibition of anti-TMP-BSA conjugate IgG binding to TMP-
BSA conjugate. The competitors were poly(G) ( Q ). 
ROS-poly(G) ( A ) . poly{dA-dT).poly(dA-dT){ A ). poly(dA-
dU).poly(dA-dU) ( # ) and poly(A).poly(U) (V)- The microtitre 
plates were coated with TMP-BSA conjugate (10 ng/ml). 
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TABLE-IV 
Competitive Inhibition Data of Anti-TMP-BSA Antibodies 
Inhibitors 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
2 1 . 
22. 
23 . 
24. 
25. 
26. 
TMP-BSA conjugate 
Maximum percent 
inhibition 
(20^g/ml) 
95a 
ROS-TMP-BSA cojugate 42 
TMP 
ROS-TMP 
Thymidine 
ROS-thymidine 
ctDNA 
ROS-ctDNA 
Thymine 
ROS-thymine 
Guanine 
ROS-guanine 
Cytosine 
ROS-cytosine 
Adenine 
ROS-adenine 
Poly(G) 
ROS-poly{G) 
Poly(I) 
ROS-poly(I) 
mtDNA 
ROS-mtDNA 
Poly(A).poly(U) 
Poly(dA-dT). 
poly(dA-dT) 
Poly{dA-dU). 
poly{dA-dU) 
Poly(dl-dC). 
poly(dl-dC) 
28 
69* 
16 
56 
48 
33 
21** 
82 
46 
61 
12 
# 
29 
59* 
45* 
40 
# 
# 
# 
# 
10 
36 
22 
# 
Concentration 
required for 
50% inhibition 
0.35 
-
-
15 
-
18 
-
-
-
5.5 
-
17 
-
-
-
1.5 
-
-
-
-
-
-
-
-
-
Percent 
relative 
affinity 
100 
-
-
2.3 
-
1.9 
-
-
-
6.3 
-
2 
-
-
-
23.3 
-
-
-
-
-
-
-
-
-
* Insignificant inhibition 
* Inhibition at 15 yig/ml 
a Inhibition at 10 ng/ml 
** Inhibition at 5 |ig/ml 
The microtiter plates were coated with TMP-BSA Conjugj 
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Fig.29 Inhibition of anti-ROS-TMP-BSA conjugate IgG binding to 
ROS-TMP-BSA conjugate. The competi tors were TMP-
BSA conjugate ( Q )• TMP { A ) , ROS-TMP ( A ) , thymidine 
( 0 ) and ROS-thymidine { .+ )• The microtitre plates were 
coated with ROS-TMP-BSA conjugate (10 pg/ml) . 
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Fig.30 Inhibition of anti-ROS-TMP-BSA conjugate IgG binding to 
ROS-TMP-BSA conjugate. The compet i tors were thymine 
( O ). ROS-thymine { A ). guanine ( A ). ROS-guanine 
( % ), adenine { V )> ROS adenine { -|- ). The microtitre 
plates were coated with ROS-TMP-BSA conjugate (10 yg / 
ml). 
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Fig.31 Inhibition of anti-ROS-TMP-BSA conjugate IgG binding to 
ROS-TMP-BSA conjugate. The competitors were 
cytosine ( O ), ROS-cytosine ( A ). native ctDNA ( A ). 
poly(G) ( # ) and ROS-poly(G) ( ^ ). The microtitre plates 
were coated with ROS-TMP-BSA conjugate (lOpg/ml). 
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Fig.32 Inhibition of anti-ROS-TMP-BSA conjugate IgG binding to 
ROS-TMP-BSA conjugate. The competi tors were poly(dA-
dT).poly(dA-dT) ( O )- poly(dA-dU).poly(dA-dU) ( A ), 
poly{dI-dC).poly(dI-dC) ( A ) and poly(A).poly(U) ( # ). The 
microtitre platen vvere coated with ROS-TMP-BSA conjugate 
(10 pg/ml) . 
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TABLE-V 
Competitive Inhibition Data of Anti-ROS-TMP-BSA Antibodies 
Inhibitors 
1. ROS-TMP-BSA 
conjugate 
Maximum percent 
inhibition 
(20ng/ml) 
98 
2. TMP-BSA conjugate 89 
3. TMP 
4. ROS-TMP 
5. Thymidine 
6. ROS-thymidine 
7. Thymine 
8. ROS-thymine 
9. Guanine 
10. ROS-guanine 
11 Adenine 
12. ROS-adenine 
13. Cytosine 
14. ROS-cytosine 
15. ctDNA 
16. ROS-ctDNA 
17. Polyl 
18. ROS-polyl 
19. PolyG 
20. ROS-polyG 
2 1 . PoIy(A).poly(U) 
22. Poly(dA-dT). 
poly(dA-dT) 
23. Poly(dA-dU). 
poly{dA-dU) 
24. Polyldl-dC). 
poly(dl-dC) 
39 
86 
23 
56 
16 
81 
55 
78 
29** 
48 
15 
17* 
27* 
# 
# 
# 
38 
53 
9 
22 
35** 
35 
Concentration 
required for 
50% inhibition 
0.5 
0.2 
-
9 
-
4.5 
-
4.5 
10 
2.5 
-
-
-
. 
. 
_ 
-
-
-
-
-
-
-
Percent 
relative 
affinity 
100 
50 
-
5.5 
-
11.1 
-
11.1 
5 
20 
. 
_ 
-
« 
_ 
_ 
_ 
-
-
. 
-
-
-
*• Inhibition at 5 ug/ml 
* Inhibition at 15 ug/ml 
# Insignificant inhibition 
The microtiter plates were coated with ROS-TMP-BSA Conjugate (10 vig/ml). 
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Detect ion of Anti-DNA Antibodies in SLE Sera 
The SLE anti-DNA autoantibodies were found to be precipitating with 
TMP-BSA and ROS-TMP-BSA conjugates as de tec ted by 
counterimmunoelectrophoresis (Fig. 33). Various SLE serum samples were 
tested for the presence of anti-DNA autoantibodies by direct binding 
ELISA (Fig. 34 and 35) (Table VI). Normal human serum showed 
negligible binding. The specificity of SLE autoantibodies binding to native 
DNA was determined by competition ELISA. Native DNA showed 
maximum inhibitions ranging from 28% to 43% in eight SLE sera (Fig. 36 
and 37). Table Vll shows the inhibition data of anti-DNA autoantibodies 
binding to DNA from these serum samples. The binding of SLE anti-DNA 
autoantibodies to TMP-BSA conjugate and ROS-TMP-BSA conjugate was 
determined by direct binding ELISA. Out of eight high titre sera, six show 
higher absorbance values for TMP-BSA conjugate as compared to its ROS-
modified form (Fig. 38). 
Purification of SLE IgG 
Protein-A binds IgG from most mammalian species through 
interactions with the Fc part of IgG molecules. SLE IgG was purified by 
affinity chromatography on Protein-A Sepharose CL-4B column. The 
purified IgG from normal and SLE sera were found to elute in a single 
symmetrical peak. The homogeneity of purified IgG was confirmed by the 
presence of a single band in SDS-PAGE, under non-denaturing conditions 
(Fig. 39). In order to investigate the binding activity of purified SLE IgG 
with native DNA. direct binding ELISA was performed. Figure 40 shows 
appreciable binding with native DNA, while normal human IgG showed 
neghgible binding. Native DNA showed maximum inhibitions ranging from 
84 
iOi-) 
(b) 
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Fig .S3 C o u n t e r i m m u n o e l e c t r o p h o r e s i s of SLE anti-DNA 
autoantibodies with TMP-BSA (a) and ROS-TMP-BSA 
conjugate (b). Electrophoresis was performed on 0 6% 
agarose gel for 2 hr at 140 V 
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Fig.34 Evaluation of anti-DNA autoantibodies in SLE patients. The 
microtitre plates were coated with native DNA. SLE serum 
1(A), 2(A), 3 ( 0 ) , 4 ( # ) , 5 (V) and NHS ( + ). 
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Fig.35 Evaluation of anti-DNA autoantibodies in SLE patients. The 
microtitre plates were coated with native DNA. SLE serum 
6(A) , 7(A) , 8 ( 0 ) . 9 ( 0 ) , 10(V) and NHS ( + ). 
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TABLE VI 
Titre of SLE Anti-DNA Autoantibodies 
SLE patients Titre 
1 1:1600 
2 1:6400 
3 1:1600 
4 >1:6400 
5 1:3200 
6 1:6400 
7 >1:3200 
8 1:3200 
9 1:400 
10 1:400 
The microtitre plates were coated with nDNA (2.5 \ig/ml) 
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Fig.36 Inhibition of anti-DNA antibody binding by native DNA with 
SLE serum 1(A), 2(0), 3(A) and 4( # ). Microtitre plates 
were coated with native DNA (2.5 pg/ml). 
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Fig.37 Inhibition of anti-DNA antibody binding by native DNA with 
SLE serum 5 ( 0 ) , 6(A), 7(A) and 8( # ). Microtitre plates 
were coated with native DNA (2.5 vig/ml). 
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TABLE-VII 
Competitive Inhibition of SLE Autoantibodies by Native DNA 
SLE Sera Maximum percent inhibition at 20 pg/ml 
1 33 
2 28 
3 38 
4 42 
5 35 
6 42 
7 40 
8 43 
The microtitre plates were coated with nDNA (2.5 jig/ml) 
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Fig.38 Binding of SLE serum antibodies (1 :100 dilution) to TMP-
BSA conjugate ( H i ) and ROS-TMP-BSA conjugate ( • • ) 
Microtitre plates were coated with 10 pg/ml of respective 
an t igens . 
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Fig.39 Elution profile of SLE IgG on Protein A-Sepharose CL-4B 
affinity column. Inset; SDS-PAGE of purified IgG on 7.5'Vi 
polyacrylamide gel. 
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Fig.40 Direct binding ELISA of normal human IgG ( A ) and SLE 
IgG ( A ) with native DNA (2.5 pg/ml). 
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Fig.41 Inhibition of anti-DNA antibody binding by native DNA with 
SLE IgG 1 ( 0 ) , 2 ( A ) , 3 ( A ) and 4 ( # ) . Microtitre plates 
were coated with native DNA (2.5 pg/ml) . 
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Fig.42 Inhibition of anti-DNA antibody binding by native DNA with 
SLE IgG 5 ( 0 ) . 6 ( A ) , 7 ( A ) and 8 ( # ) . Microtitre plates 
were coated with native DNA (2.5 jag/ml). 
SLE IgG 
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TABLE-VIII 
Competitive Inhibition of SLE IgG by Native DNA 
Maximum percent 
inhibition at 
20 ng/ml 
39 
32 
49 
54 
42 
55 
52 
55 
Concentration required 
for 50% inhibition (pg/ml) 
-
-
-
17 
-
19 
16 
19 
1 
2 
3 
4 
5 
6 
7 
8 
The microtitre plates were coated with nDNA (2.5 ng/ml). 
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32% to 5 5 % in eight SLE IgGs (Fig. 41 and 42). Table VIII summarizes 
the maximum inhibition of SLE IgG with native DNA. 
Binding of Anti-DNA Antibodies with Native and ROS-Modified 
Conjugates . 
The specificity of each SLE IgG for native and ROS-TMP-BSA 
conjugates were evaluated by inhibition assays. In this case, the SLE JgG 
was first incubated with native and modified conjugates and then assayed 
for residual binding to double stranded DNA. The microtitre plates were 
coated with native DNA. TMP-BSA conjugate showed maximum 
inhibitions ranging from 32% to 85% (Fig. 4 3 and 44). ROS-TMP-BSA 
conjugate showed relatively low percent inhibition as compared to its 
native form (Fig. 45 and 46). Table IX and X summarizes the inhibition 
results of anti-DNA autoantibodies binding to native DNA by TMP-BSA 
and ROS-TMP-BSA conjugates. 
Detect ion of Circulating Antibodies in Cancer Sera 
For this study, 45 serum samples were collected from patients 
suffering from cancer of different organs/organ systems. Cancer sera 
were obtained after careful clinical examination of patients with proven 
histopathological diagnosis attending J.N. Medical College Hospital. 
A.M.U., Aligarh. Sera from normal, healthy individuals served as controls. 
The binding of circulating antibodies in cancer sera (at 1:100 
dilution) with TMP-BSA conjugate and ROS-TMP-BSA conjugate was 
assessed by direct binding ELISA. Out of eight breast cancer sera tested, 
six showed higher recognition of ROS-TMP-BSA conjugate (Fig. 47). Oral 
cancer sera recognizes both native and ROS-modified conjugates (Fig. 48). 
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Fig.43 Inhibition of anti-DNA antibody binding by TMP-BSA conjugate. 
Curves { Q ) , ( A ). ( A ) and ( % ) represent 4 different 
SLE IgG with TMP-BSA conjugate as inhibitor. The 
m\CYotUTe plates were coated with native DNA (2.5 vis/^ n l^) 
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Fig.44 Inhibition of anti-DNA antibody binding by TMP-BSA 
conjugate. Curves ( O ). ( A )• ( A ) and ( # ) represent 
4 different SLE IgG with TMP-BSA conjugate as inhibitor. 
The microtitre plates were coated with native DNA (2.5 \IQ/ 
ml). 
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TABLE-DC 
Inhibition of Anti-DNA Autoantibodies by TMP-BSA conjugate 
SLE IgG Maximum percent inhibition Concentration required 
at 20 pg/ml for 50% inhibition (pg/ml) 
1 32 
2 38 
3 45 
4 61 2.5 
5 36* 
6 85 0.7 
7 57 15 
8 73 0.5 
* Inhibition at 5 |ig/ml 
The microtitre plates were coated with nDNA (2.5 ng/ml) 
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Fig.45 Inhibition of anti-DNA autoantibodies binding by ROS-TMP-
BSA conjugate. Curves ( O ^ ( A )< ( A ) ^"^1 ( # ) 
r e p r e s e n t 4 different SL^. IgG with ROS-TMP-BSA 
conjugate o inhibitor. The microtitre plates were coated 
with native DNA (2.5 pg/ml). 
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Fig.46 Inhibition of anti-DNA autoantibodies binding by ROS-TMP-
BSA conjugate. Curves ( Q )• ( A ), ( A ) and { % ) 
r ep r r^pn t 4 different SLE IgG with ROS-TMP-BSA 
conjugate as inhibitor. The microtitre plates were coated 
with native DNA (2.5 \iQ/m\). 
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TABLE- X 
Inhibition of Anti-DNA autoantibody binding by ROS-TMP-BSA 
conjugate 
SLE IgG Maximum percent inhibition Concentration required 
at 20 ng/ml for 50% inhibition (ng/ml) 
1 14 
2 10 
3 29 
4 42 
5 31 
6 52 17 
7 36 
8 36 
The microtitre plates were coated with nDNA (2.5 pg/ml) 
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Fig 47 Binding of breast cancer serum samples (1:100 dilution) to 
TMP-BSA ( H ) and ROS-TMP-BSA conjugates ( ^ ) Normal 
human serum (NHS) showed negligible binding to either of 
antigens Microtitre plates were coated with 10 ug/ml of 
respective ant igens. 
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Fig.48 Binding of oral cancer serum samples (1 :100 dilution) to 
TMP-BSA conjugate ( • ) and ROS-TMP-BSA conjugate 
{|^). Normal human serum (NHS) showed negligible binding 
to either of antigens. Microtitre plates were coated with 
10 pg/ml of respective ant igens. 
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Direct binding results of sera from tonsil cancer patients revealed similiar 
binding with native and ROS-modified conjugates (Fig. 49). Out of five 
serum samples from cancer of gall bladder, three gave higher binding with 
ROS-TMP-BSA conjugate, while one serum showed appreciable binding 
with TMP-BSA conjugate (Fig. 50). Serum samples from patients with liver 
cancer showed binding to both native and ROS-modified forms. Two sera 
showed slightly higher binding towards ROS-modified conjugate (Fig. 51). 
Similiarly, sera from lung and larynx cancer revealed preferential binding 
with ROS-modified conjugate (Fig. 51). 
The binding specificity of antibodies in cancer sera were analyzed by 
competitive binding assay. Six sera were tested from patients suffering 
from breast cancer (Aged 40 to 65 years). Out of these six, only two sera 
showed moderate inhibition with TMP-BSA conjugate. Two sera showed 
almost similiar level of inhibition for native (31% and 27%) and ROS-
modified conjugate (29% and 30%), while the other two serum samples 
showed reactivity to a lesser extent with native and ROS-modified TMP-
BSA conjugate? (Fig. 52). 
Among the seven serum samples from patients with cancer of oral 
cavity (four males, 40 to 65 years old and three females, 30 to 55 years 
old), three showed moderate but higher inhibition to TMP-BSA conjugate 
than ROS-TMP-BSA conjugate . Two sera showed slight higher inhibition 
of 14% and 26% as compared to 8% and 18% with TMP-BSA conjugate 
(Fig. 53). Two serum samples among these seven samples showed no 
inhibition with either of the antigens (Table XI). 
Three sera (two male and one female) were from patients with 
hepatocellular (liver) carcinoma. All three sera had antibodies with a 
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Fig 49 Binding of tonsil cancer serum samples (1 100 dilution) to 
TMP-BSA ( B ) and ROS-TMP-BSA conjugates ( ^ ) Normal 
human serum (NHS) showed negligible binding to either of 
antigens Microtitre plates were coated with 10 ng/ml of 
respective antigens 
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Fig 50 Binding of gall bladder cancer serum samples (1 100 
dilution) to TMP-BSA ( • ) and ROS-TMP-BSA conjugates 
( O ) Normal human serum (NHS) showed negligible binding 
to either of antigens Microtitre plates were coated with 
10 jjg/ml of respective antigens 
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Fig .51 Binding of liver (n = l - 3 ) . lung (n = 4-6) and larynx (n = 7-S) 
cance r sera samples ( 1 : 1 0 0 dilution) to TMP-BSA ( | ) 
and ROS-TMP-BSA ( ^ ) conjugates . Norma l h u m a n serum 
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an t i gens . 
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Fig.52 Detection of antibodies against TMP-BSA (a) and ROS-TMP-
BSA conjugates (b) in the sera of pat ients with breast 
cancer. The microtitre plates were coated with ROS-TMP-
BSA conjugate (10 pg/ml). The curves ( A ) . ( O )- ( A )• 
( # ) and { V ) represent sera from different patients. 
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Fig.53 Detection of antibodies against TMP-BSA (a) and ROS-TMP-
BSA conjugates (b) in the sera of patients with oral cancer. 
The microti tre plates were coated with ROS-TMP-BSA 
conjugate (10 pg/ml). The curves ( A ) . ( O )• ( A ). ( • ) 
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Fig.54 Detection of antibodies against TMP-BSA (a) and ROS-TMP-
BSA conjugates (b) in the sera of pat ients with liver cancer. 
The microtitre plates were coated with ROS-TMP-BSA 
conjugate (10 pg/ml). The curves ( A )• ( O ) and ( A ) 
represent sera from different pat ients . 
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higher recognition to ROS-TMP-BSA conjugate (32%, 34% and U%), 
whereas TMP-BSA conjugate was inhibited to a lesser extent (11%. 21% 
and 25%) (Fig. 54) 
Three samples were collected from patients with lung cancer (all 
males, aged 30 to 55 years). All these serum samples showed higher 
inhibition wih ROS-TMP-BSA conjugate (37%, 35% and 46%) than 
towards TMP-BSA conjugate (15%, 20% and 33%) (Fig. 55). The results 
point out conclusively to a higher reactivity of antibodies in lung cancer 
sera towards ROS-modified TMP-BSA conjugate over unmodified 
conjugate. 
Four sera (all from females) were from patients suffering from cancer 
of the gall bladder. Antibodies in these serum samples showed preferential 
binding i.e., higher inhibition with ROS-modified conjugate (37%, 52'%. 
43% and 47%) over unmodified TMP-BSA conjugate (33%, 23%, 27% and 
30%) (Fig. 56). Four sera were from patients with tonsil cancer. Two sera 
showed higher recognition of TMP-BSA conjugate (34% and 39%) over 
ROS-modified conjugate (17% and 35%).. The other two sera showed 
almost same reactivitiy with native (50% and 45%) and ROS-modified 
conjugates (53% and 43%) (Fig. 57). 
Two sera were collected from patients with carcinoma of larynx. One 
serum showed preferential binding with TMP-BSA conjugate (40%) over its 
ROS-modified form (33%). The other serum showed a higher recognition 
for ROS-TMP-BSA conjugate (25%) over its native form (17%) (Fig. 58). 
Sera from patients with carcinoma of cervix and rectum showed no 
inhibition with either native or its ROS-modified form. The binding data 
of the cancer sera are summarized in Table XI. 
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Fig.55 Detection of antibodies against TMP-BSA (a) and ROS-TMP-
BSA conjugates (b) in the sera of patients with lung cancer 
The microtitre plates were coated with ROS-TMP-BSA 
conjugate (10 |ig/ml). The curves ( A )- ( O ) arid ( A ) 
represent sera from different pat ients . 
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Fig.56 Detection of antibodies against TMP-BSA (a) and ROS-TMP-
BSA conjugates (b) in the sera of patients with gall bladder 
cancer. The microtitrc plates were coated with ROS-TMP-
BSA conjugate (10 pg/ml). The curves ( A ). ( O )• ( A ) 
and ( 0 ) represent sera from different patients. 
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Fig.57 Detection of antibodies against TMP-BSA (a) and ROS-TMP-
BSA conjugates (b) in the sera of patients with tonsil 
cancer. The microtitre plates were coated with ROS-TMP-
BSA conjugate (10 ng/ml) . The curves ( A ) . ( O )• ( A ) 
and ( A ) represent sera from different pat ients . 
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Fig.58 Detection of antibodies against TMP-BSA (a) and ROS-TMP-
BSA conjugates (b) in the sera of patients with larynx 
cancer. The microtitre plates were coated with ROS-TMP-
BSA conjugate (10 pg/ml). The curves ( A ) and ( Q ) 
represent sera from different pa t ients . 
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TABLE-XI 
Inhibition of Circulating Antibodies in Cancer Sera with TMP-BSA 
and ROS-modified TMP-BSA Conjugates 
— \ 
Tybe of 
Cancer 
1 
Breast 
On il 
1 
Liver 
Luitg 
Gall bladder 
Torisil 
1 
Cer^ vix 
Larynx 
Rectum 
No. of sera 
tested 
6 
7 
3 
3 
4 
4 
2 
2 
Maximum percent 
inhibition by 
TMP-BSA conjugate 
(20 pg/ml) •* 
43*, 28, 31, 26 
41 , 27 
8. 18, 31, 35 
30, #, # 
11. 21 , 25 
15. 20. 33 
33, 23, 27*. 30 
50. 34, 45, 39 
#, # , # 
40. 17 
#, # 
Maximum percent 
inhibition by 
ROS-TMP-BSA 
conjugate(20 pg/ml) 
27. 2 1 , 29, 15, 
31 , 30 
14. 26, 19, 27, 
26, #, # 
32. 34. 41 
37. 35, 46 
37, 52*, 43, 47 
53. 17. 43, 35 
#, # , # 
33. 25 
# . # 
The microtitre plates were coated with ROS-TMP-BSA conjugate (10 ug/ml) 
* Inhibition at 10 pg/ml 
* Insignificant inhibition 
** Maximum inhibition in case of each cancer sera has been indicated. 
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Binding characterist ics of IgG from Cancer Sera 
Cancer IgG was isolated and purified by affinity chromatography on 
Protein A-Sepharose column. The IgG eluted in a single symmetrical peak. 
Us purity was checked by SDS-PAGE under non-denaturing conditions. 
Purified cancer IgG was investigated for antibodies against TMP-BSA 
conjugate and its ROS-modified form. Immune complexes were made 
between native and ROS-modified conjugate and purified IgG. Microtitre 
plates were coated with ROS-TMP-BSA conjugate. IgG was isolated from 
four patients with breast cancer. All the IgGs showed higher recognition 
of ROS-modified conjugate over that of native conjugate. One of them 
showed a maximum inhibition of 62% with ROS-TMP-BSA conjugate (Fig. 
59). Two IgG isolated from hepatocellular carcinoma showed higher 
recognition of ROS-TMP-BSA conjugate (maximum inhibition of 38'/o and 
49%) over that of TMP-BSA-conjugate (maximum inhibition of 28% and 
32%) (Fig. 60). Similar results were obtained with the IgG isolated from 
patients with gall bladder cancer. In this case, maximum inhibitions of 
43% and 57% for ROS-modified conjugate, and only 30"/n and 38% was 
observed with TMP-BSA conjugate (Fig. 61). IgG isolated from five 
patients with oral cancer showed varied results. Out of these five IgGs. 
four showed maximum inhibitions with TMP-BSA conjugate (30%, 42%, 
52% and 59%) than towards ROS-modified conjugate (28%, 23%, 44% 
and 27%). One IgG showed almost similar reactivity to TMP-BSA and its 
ROS-modified form (43% and 40%, respectively) (Fig. 62). The binding 
data of the purified IgG to native and ROS-modified TMP-BSA conjugate 
is summarized in Table XII. 
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Fig.59 Detection of antibodies against TMP-BSA (a) and ROS-TMP-
BSA conjugates (b) in the purified IgG isolated from sera 
of patients with breast cancer. The microtitre plates were 
coated with ROS-TMP-BSA conjugate (10 Mg/ml). The 
curves { A ), ( O )> ( A ) and ( ^ ) represent sera 
from different patients. 
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Fig.60 Detection of antibodies against TMP-BSA (a) and ROS-TMP-
BSA conjugates (b) in the purified IgG isolated from sera 
of patients with liver cancer. The microfitre plates were 
coated with ROS-TMP-BSA conjugate (10 pg/ml). The 
curves ( Q ) and { A ) represent sera from different patients. 
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Fig.61 Detection of antibodies against TMP-BSA (a) and ROS-TMP-
BSA conjugates (b) in the purified IgG isolated from sera 
of patients with gall bladder cancer. The microtitre plates 
were coated with ROS-TMP-BSA conjugate (10 pg/ml). The 
curves ( O ) and ( A ) represent sera from different patients. 
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Fig.62 Detection of antibodies against TMP-BSA (a) and ROS-TMP-
BSA conjugates (b) in the purified IgG isolated from sera 
of patients with oral cancer. The microtitre plates were 
coated with ROS-TMP-BSA conjugate (10 pg/ml) . The 
curves ( A ), { O ). ( A ) ( # ) and ( ^ ) represent sera 
from different pa t ients . 
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TABLE-XII 
Competitive Inhibition Data of Cancer IgG with TMP-BSA and ROS-
TMP-BSA Conjugates. 
Type of 
cancer 
No. of IgG 
tested 
Maximum percent 
inhibition by 
TMP-BSA conjugate 
(20 ug/mi) 
Maximum percent 
inhibition by 
ROS-TMP-BSA 
conjugate(20 ug/ml) 
Breast 20. 37. 33. 48 43. 43, 5 1 . 62 
Liver 28, .32 38, 49 
Gall bladder 30. 38 43, 57 
Oral 30, 42, 52, 59. 43 28, 23, 44, 27. 40 
The microtitre plates were coated with ROS-TMP-BSA conjugate (10 |jg/ml) 
DISCUSSION 
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Antibodies reactive with a number of nuclear antigens have been 
found in the sera of patients with systemic lupus erythematosus (SLE). 
Their entire spectrum is unknown, but there is considerable data 
suggesting that a single antigen', such as DNA may command a broad 
heterogeneity of antibodies with specificity towards receptor sites that are 
quite variable not only from patient to patient but even in the same 
patient (Arana and Seligman, 1967; Stollar, 1967; Stollar and Levine, 
1963; Stollar et al., 1962a & b). These naturally occurring antibodies 
not only provide diagnostic/prognostic parameters to clinicians but give 
molecular biologists valuable tools for the better understanding of cellular 
processes (Woodruff et a/., 1986). The binding diversity of lupus 
autoantibodies to a whole spectrum of modified nucleic acid conformers 
seems to be enormous (Arif et al., 1995; Arjumand et al., 1995: 
Arjumand and Ali, 1994; Klinman et al., 1994; Moinuddin and All. 
1994; Alam et al., 1992 & 1993; Alam and Ali, 1992; Ah et al.. 
1991). Efforts to understand the origin and consequence of anti-dsDNA 
antibodies are still in progress. 
Association between neoplasia and autoimmunity has been described 
with an increasing frequency during the last two decades. Similarly, 
various autoantibodies have been identified in the sera of patients with 
epithehal and hematologic malignancies (Vainio et al.. 1983; Nelson. 
1977). Elevated titres of antinuclear antibodies (ANA) upto 27% in cancer 
sera have been reported (Bunham, 1972; Fairley. 1972; Zeronski et al.. 
1972). Increased levels of circulating antibodies and autoantibodies have 
been reported in the serum of patients with malignancies directed against 
the nucleus, smooth muscle (Imai et al.. 1993) and phosphoHpids (Becker 
et al.. 1994). 
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It has been suggested that antibodies in lupus sera are primarily 
directed to the DNA bases (Stollar et a/., 1962b). There may be 
however, some antibodies in this complex family which are reactive with 
the deoxyribosephosphate backbone and nucleotide but not with the 
corresponding nucleoside, suggesting that the antigenic determinant might 
be shared by the base and the sugar-phosphate moiety. While, in some 
sera reaction occurred with the nucleoside but not with the corresponding 
nucleotide, probably indicating interference of the negative charge of 
phosphate with the antigen-antibody reaction (Alarcon-Segovia et a/.. 
1970). Guanine and thymine are prominent as components of nucleotides 
and oligonucleotides that react with certain antibodies (Lee et al., 1981; 
Eilat et al., 1980). 
Reactive oxygen species (ROS), generated during various metabohc 
and biochemical reactions have multifarous effects that include oxidative 
DNA damage leading to various human degenerative diseases (Halliwell 
and Cross, 1994; Halliwell, 1989). Among the ROS, hydroxyl radical 
(OH) the highly reactive oxygen species can interact with the chromatin 
and result in a wide variety of sugar and base derived products, DNA-
protein crosslinks, single and double strand breaks (Gajewski et al., 1990; 
Dizdaroglu and Bergtold, 1986), showing the mutagenic and carcinogenic 
potential of this radical (Jaruga et al., 1994). ROS modified-DNA has 
been found to be a better antigen for anti-DNA autoantibodies present in 
SLE sera (Alam et al., 1993; Ara and AU, 1992). Experimentally induced 
antibodies against ROS-modified DNA exhibit polyspecificity (Ara and All. 
1993) recognizing B, A and allied conformations of DNA (Ara and All. 
1995). DNA isolated from SLE patients showed high recognition by Mab 
having preferential binding with ROS-modified epitopes which indicates 
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increase oxidative stress in these patients leading to DNA damage (Ahmad 
et al., 1998). Thymine base is highly susceptible to "OH modification to 
form products such as thymineglycol (Tg) and 5-hydroxymethyluracil. 
These modified bases have also been detected in human urine together 
with 8-hydroxydeoxyguanosine, indicating that their formation is due to 
oxidative s t ress to DNA (Halliwell and Aruoma, 1991) . 8-
hydroxyguanosine is a major mutagenic lesion associated with an 
increased risk of cancer, whereas there is no such distinct association with 
ROS-modified thymine products. For these reasons, it was thought 
desirable to investigate the immunogenicity of ROS-modified thymidine 
monophosphate and its possible role in SLE and development of cancer. 
In t h e p r e s e n t study, a deoxyr ibonuc leo t ide , thymidine 
monophosphate (TMP) was modified by hydroxyl radical, generated by 
irradiation of hydrogen peroxide with 254 nm UV light. The characteristic 
absorption pattern was lost as a result of the damage caused by the 
hydroxyl radical. UV difference spectra of ROS-modified TMP with 
reference to native TMP shows a negative undefined trough, clearly 
indicating the marked change in the modified nucleotide. This could be 
due to the structural alterations and modifications of thymine base. 
Antibodies against TMP and ROS-modified TMP were induced in 
rabbits by complexing with methylated bovine serum albumin. Both native 
and ROS-TMP were found to be non-immunogenic as revealed by 
counterimmunoelectrophoresis, direct binding and inhibition ELISA 
results. Our results correlate with earlier findings that nucleotides by 
themselves are not capable of inducing antibodies. Therefore, nucleotides 
can be conjugated to a carrier protein by carbodiimide method (without 
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cleaving the ribose/deoxyribose ring) utilising the phosphate group 
present in them to enhance their antigenicity (Chandira Kala and Antony, 
1996). 
Thymidine monophosphate was hnked with BSA and the conjugate 
characterized by ultraviolet absorption spectra. A slight bathochromic shift 
in \^^ was observed. The results of polyacrylamide gel electrophoresis 
reiterate the formation of a TMP-BSA conjugate.The TMP-BSA conjugate 
was modified with hydroxyl radical. A substantial decrease in absorption 
was observed at X^^^. This could be attributed to the fact that hydroxyl 
radicals produced by UV irradiation, simultaneously cause damage to 
TMP-BSA conjugate. UV difference spectra of ROS-TMP-BSA conjugate 
with reference to TMP-BSA conjugate shows a negative peak at X^ ^^ ,^ 
clearly indicating the marked hypochromicity of the modified conjugate. 
This could be due to structural alterations in thymine base. 
The spectral changes at 30"C and 95"C were also recorded. An 
appreciable degree of hyperchromism was displayed by UV spectral curves 
of ROS-modified TMP-BSA conjugate when thermally agitated to 95"C. 
Hydroxyl radical abstracts hydrogen atoms from deoxyribose, giving rise 
to sugar radical that can fragment in various ways. Photochemical changes 
have also been found to occur in purine and pyrimidine bases on attack 
of 'OH radical (Halliwell and Aruoma, 1991). The pyrimidine bases in 
DNA are attacked to give several products like thymine and cytosine 
glycols (Breen and Murphy, 1995). 
The elution pattern of 'OH modified TMP-BSA conjugate was studied 
by gel chromatography through a Sephadex G-lOO column. The 
broadening of major peak of ROS-TMP-BSA conjugate in contrast to the 
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sharp peak of TMP-BSA conjugate suggests that hydroxyl radical causes 
stuctural perturbations of the thymine • residues. The presence of low 
molecular weight species was further ascertained by densitometric 
scanning of native and ROS modified conjugate following electrophoresis 
on 7.5% native polyacrylamide gel. The hydroxyl radical is highly 
electrophilic and thus preferentially attacks the site of highest electron 
density, that is C-5. In thymine, the methyl group reduces the amount of 
attack at C-5 by steric hindrance and stabilizes the C(6) OH-5-yl radical 
adduct sHghtly, thus reducing the C(5) OH:C(6)OH ratio (Pryor, 1988). 
Native DNA is known to be a poor immunogen (Stollar, 1986; 
Madaio et a!., 1984), whereas, double stranded RNA. RNA-DNA hybrid, 
double helical polydeoxyribonucleotides. synthetic ribohomopolymers 
poly(I), poIy(G), poly(U) and calf thymus DNA modified with drugs, 
hormones, free radicals, etc., have been reported to induce antibodies 
(Garg and AH, 1998; Arjumand et al., 1997; Arif and AH, 1996; Hasan 
et a/., 1995; Theofilopoulous, 1 9 9 5 ; Moinuddin and Ali, 1994; Desai et 
a\.. 1993; Anderson et a/.. 1 9 8 8 ; Stollar. 1973. 1975 & 1986) 
Antibodies to dihydrothymidine were elicited by immunizing rabbits with 
dihydrothymidine monophosphate conjugated by carbodiimide to BSA 
(Hubbard et a1., 1989). The present studies demonstrate the fine 
immunogenicity of TMP-BSA conjugate and its hydroxyl radical modified 
counterpart i.e., ROS-TMP-BSA conjugate. 
Direct binding and inhibition ELISA revealed high immunogenicity of 
both native and ROS modified TMP-BSA conjugate. A maximum of 95% 
inhibition of anti TMP-BSA conjugate antibody (serum) binding to TMP-
BSA conjugate was observed. Fifty percent inhibition in the antibody 
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activity was achieved with 2 ng/ml of TMP-BSA conjugate. Purified anti-
TMP-BSA IgG was inhibited to an extent of 95% (at 10 ng/ml) and 50% 
inhibition was observed with only 0 .35 |ig/ml of TMP-BSA conjugate. The 
data clearly indicate the higher specificity of purified IgG as compared to 
serum activity towards TMP-BSA conjugate. ROS-TMP-BSA conjugate 
showed a maximum inhibition of 42%. ROS-modified TMP, thymidine and 
thymine showed higher inhibitions of 69%, 56% and 82% respectively, 
whereas, unmodified forms showed lower inhibitions of 27%, 16% and 
18%. respectively. The data indicates the specificity of IgG towards the 
ROS-modified form of conformers (than their native forms), preferably 
recognizing the common epitope, the phosphodiester backbone. ROS-
adenine and ROS-guanine shows a high inhibitory potential of 57% and 
6 1 % than their native forms. Poly (I), ROS-poly (I) and ROS-poly (G). 
superoxide DNA and mitochondrial DNA showed insignificat inhibition. 
Inhibition studies by poly(dA-dT).poIy(dA-dT) shows the polyreactivity of 
the induced antibodies. Experimentally induced antibodies to conjugates of 
BSA with purines or pyrimidines are quite specific for the base used, but 
cross-react extensively with nucleic acids from numerous sources which 
contain the individual base (Alarcon-Segovia et al., 1970). 
Purified anti-ROS-TMP-BSA conjugate IgG showed a maximum 
inhibition of 98% (92% with serum) with ROS-TMP-BSA conjugate. Fifty 
percent inhibition was attained with only 0.5 |.ig/ml of ROS-TMP-BSA 
conjugate (2.5 ng/ml in case of serum). This indicates the higher 
specificity of purified immune IgG than serum activity. Inhibition data 
showed cross-reactivity of IgG with various nucleic acid polymers. The 
TMP-BSA conjugate gave a maximum inhibition of 89%. ROS-modified 
TMP, thymidine and thymine showed higher inhibitions (86%. 56*'/o and 
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81%) than their unmodified counterparts (39%, 23% and 16%). Double 
stranded polynucleotides poly(dA-dU).poly(dA-dU) and poly{dl-dC). 
poly{dI-dC) showed inhibition of 35% each. This broad polyspecificity of 
the induced antibodies with a variety of polynucleotides might be due to 
the recognition of the phosphodiester-backbone (Ballard and Voss, 1982). 
ROS-guanine showed a high inhibitory potential of 78% than native 
guanine (55%). This indicates that the immune IgG is more specific to the 
ROS-modified epitopes on guanine. Earlier reports have demonstrated 
guanine to be highly susceptible to 'OH modification leading to the 
formation of 8-hydroxyguanosine (Garg and Ali, 1998; Lunec et a/., 
1994). 
The SLE autoantibodies react with dsDNA from a wide range of 
species (Pisetsky, 1996). It has been proposed that in chronic 
inflammatory diseases such as SLE, the phagocytic cells release reactive 
oxygen species (Allan et a/., 1988) which penetrate cellular membranes 
and react with nuclear DNA (Bashir et al., 1993). Subsequent release of 
this altered DNA during apoptosis, may enable it to act as an antigen 
inducing autoantibodies cross-reacting with native DNA (Casciola-Rosen 
and Rosen, 1997; Herrman et al., 1996). It was suggested that DNA 
antibodies appear to be directed predominantly against other determinants 
that include the purine and pyrimidine bases (Munns et al., 1984). 
In the present study, anti-double stranded DNA autoantibodies were 
screened from patients with SLE by direct binding and inhibition ELISA. 
Results with purified SLE IgG showed appreciable binding with native 
DNA and inhibition varies from 32% to 55%. When reactivity of TMP-BSA 
conjugate and its ROS modified form was probed, direct binding ELISA 
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reiults showed the preferential binding of TMP-BSA conjugate over ROS-
TMP-BSA conjugate. Further, competition immunoassay substantiated the 
above results with TMP-BSA conjugate showing inhibition ranging from 
32% to 85%, while ROS-modified TMP-BSA conjugate shows inhibitions 
in the range of 10% to 52%. 
SLE antibodies that interact with the bases can also bind to 
nucleoside-protein conjugates (Munns et a/., 1984; Alarcon-Segovia et 
al., 1970). Such conjugates can absorb nearly all of the anti-denatured 
DNA activity of certain murine lupus sera (Munns et al., 1984). Both 
murine and lupus sera with anti-denatured DNA antibodies react 
predominantly with guanosine-protein conjugates in ELISA (Zouali and 
Stollar, 1986). Conjugation of nucleotide was required for a reaction of 
measurable affinity. Similiarly, free nucleosides or mononucleotides often 
bind only at high concentrations, if at all, to SLE serum antibodies 
(Casperson and Voss, 1983). When nucleosides and nucleotides are 
presented on macromolecule carriers, the great increase in binding 
suggests that the optimal determinant is larger than the base of a single 
nucleotide and that bivalent binding of antibody to one molecule of 
antigen is required for measurable affinity (Zouali and Stollar, 1986). 
The presence of autoantibodies in the sera of cancer patients were 
also studied. The study, consisted of 45 sera from patients with various 
types oi malignancies. Most of the sera showed positive recognition and 
binding to TMP-BSA conjugate and its ROS-modified form. Sera from 
normal healthy individuals showed little or no reactivity with TMP-BSA 
conjugate and ROS-TMP-BSA conjugate . Earlier studies have 
demonstrated increased levels of circulating antibodies and autoantibodies 
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in the serum of patients with mahgnancies (Becker et a/., 1994; Imai 
et a/., 1992). In particular, elevated titres of ANA have been correlated 
with the clinical course of the disease in breast cancer (Turnbull et al.. 
1978) and hepatocellular carcinoma (Imai et al., 1992 & 1993). 
The data presented here clearly indicates the presence of circulating 
antibodies in cancer sera reactive to TMP-BSA and ROS-TMP-BSA 
conjugate. A high proportion of sera (7 out of 8) from breast cancer 
showed reactivity to these antigens. When competition immunoassay was 
performed with purified IgG isolated from 5 high titre breast cancer sera, 
it showed higher reactivity towards ROS-modified TMP-BSA conjugate. It 
has been well accepted and estabhshed that ROS damage to DNA plays a 
fundamental role in carcinogenesis, particularly of breast cancer (Ashok 
and Ah, 1998; Ashok et al., 1997; MaHns et al., 1996; Jaiyesimi et al.. 
1992). A high degree of reactivity of autoantibodies to ROS-TMP-BSA 
conjugate was observed in our study substantiating these observations. 
Lung and hepatocellular cancers are also strongly correlated with oxidative 
DNA damage (Olinski et al., 1992; Mc Elride et al., 1991). Oxidative 
damage to DNA is postulated to be a major event in the development of 
these cancers. It would be interesting to note that two sera from patients 
with hepatocellular carcinoma also had chronic hepatic infections which 
could again explain the onset of cancer as described earher (Stein. 1991: 
Beasley. 1988). Inhibition ELISA results with purified cancer IgG further 
reiterates the preferential binding of ROS-TMP-BSA conjugate over TMP-
BSA conjugate. Hepatocellular carcinoma is actively associated with DNA 
damage and mutations by aflatoxin (Loeb and Preston. 1986) or viral 
hepatitis infections leading to free r,adical generation (Shimoda et al.. 
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1994; Chisari et a/., 1989). Similiar results were obtained with sera from 
cancer of lung and gall bladder. 
Recent results from our laboratory suggest that the anti-ROS-DNA 
monoclonal antibodies has been clearly shown to represent an alternative 
immunochemical probe to detect oxidative lesions in DNA from cancer 
patients (Ashok and Ah, 1998). EarUer studies report the use of antibodies 
to specific DNA base alterations, DNA-carcinogen adducts or to UV-DNA 
{Yin et a\., 1995; Herbert et a/.; 1994). Our results also demonstrate the 
presence of anti-ROS-TMP-BSA conjugate antibodies in cancer patients 
sera, which could perhaps have a prognostic significance. 
Conclusions 
Based on the above studies, the following conclusions can be drawn. 
1. TMP per se was found to be non-immunogenic in experimental 
animals. 
2. TMP was linked with BSA through carbodiimide resulting in the 
formation of TMP-BSA conjugate. 
3. TMP-BSA conjugate was modified with HgOgin presence of UV Hght. 
for the generation of OH radical, resulting in the formation of strand 
breaks and modification of thymine base as characterized by various 
physico-chemical techniques. 
4. Both native and ROS-modified TMP-BSA conjugates were found to be 
highly immunogenic, in experimental animals. The induced antibodies 
were precipitating in nature. 
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5. The induced antibodies though, highly specific for the immunogen, 
exhibited some cross-reactivity with various nucleic acid polymers, 
thus resembling the binding characterstics of SLE anti-DNA 
antibodies. 
6. TMP-BSA conjugate as compared to ROS-TMP-BSA conjugate 
provides higher inhibitory potential to SLE anti-DNA autoantibodies 
which points out the presence of unique potential epitopes on 
TMP-BSA conjugate. 
7. IgG isolated from sera of cancer patients recognize and bind to ROS-
modified TMP-BSA conjugate. 
8. It is suggested that thymidine 5-monophosphate linked with BSA 
might serve as a diagnostic marker for SLE. 
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